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SUMMARY
Dementia is a syndrome characterized by failure of recent memory and other
cognitive functions that is usually insidious in onset but steadily progresses with age.
Alzheimer’s  disease  (AD)  is  the  most  common  form  of  senile  dementia.  It  is
neuropathologically  characterized by extracellular  and perivascular  aggregation  of
amyloid β (Aβ) peptide, by the generation of intracellular neurofibrillary tangles due to
a  hyperphosphorylation  of  tau  protein  and  by  an  increased  rate  of  neuronal
degeneration. The degenerative process starts 20-30 years before the clinical onset
of  the disease.  Clinical  diagnosis of  AD is  difficult  but  possible,  but  can only  be
confirmed by biopsy or  autopsy.  At  present,  no biological  marker  exists for  early
diagnosis of AD during life. Therefore, identification of biomarkers for AD would be of
great value for clinical diagnosis of incipient AD.
Recent studies have proven the involvement of inflammatory processes in the
neurodegenerative  events  in  AD.  Inflammation  may  not  be  the  first  event  in  the
progression of the disease, but it involves activation of glia cells including microglia
and  astrocytes  and  subsequent  release  of  proinflammatory  mediators.  Cytokines
released such as IL-1, TNF-α and IL-6 are the main proinflammatory cytokines that
can modulate inflammatory responses as well as glial proliferation and activation.
Oxidative stress triggered by inflammatory processes causes changes in  proteins
such  as  tyrosine  nitration  or  lipid  peroxidation.  Aβ  deposits,  tau
hyperphosphorylation, inflammation and oxidative stress may finally lead to changes
in synaptic connectivity and efficacy including perturbation of long-term potentiation
(LTP), important in the formation of memory. 
Proteomic technology used in these studies is a recent technology which is a two
step  process:  separation  of  proteins  and  their  subsequent  analysis  by  mass
spectrometry. Moreover, this technology can provide new information concerning the
expression level, post-translational modification of specific proteins as well as their
conformational  changes during disease progression.  In  our  study,  this technology
was modified  and improved,  e.g  by  the  miniaturization  of  the  complete  process.
Proteomic  technology  was  also  used  in  parallel  with  other  methods  such  as
chromatography  in  order  to  increase  the  sensitivity  of  detection  by  mass
spectrometry.
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This study aimed: 
1)  To  establish  that  cytokine  treatment  of  human  microglia  cells  is  an  efficient
method to study certain aspects of  AD pathogenesis.  For this analysis, a map of
protein expression in normal and in treated microglia cells was made. 
2) To map protein expression in APP/PS2 transgenic mice, a model for human AD,
in order to compare human AD brain with murine models. 
3)  To  identify  highly  nitrated  proteins  in  brains  of  transgenic  animals.  Several
proteins were found to be modified after injury.
 4) To provide evidence for instability of synapses in AD brains. To start with this
study, the technologies used to map mouse brain cytosolic proteins were improved.
5) To isolate synaptosomal membranes from the whole brain and to analyse it by
mass-spectrometry. For mapping synaptic membrane protein expression in controls
or transgenic mouse models, the technology was miniaturizated and optimized. This
study is still in progress. 
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I- INTRODUCTION
I.1- INFLAMMATION AND ALZHEIMER’S DISEASE
I.1.1-    Alzheimer’s  disease  
Neuropathological changes in brains of patients with age-related dementia have first
been described in 1906 by Alois Alzheimer, a Bavarian psychiatrist. This disorder,
which was later named Alzheimer’s disease (AD), was for a long time not recognized
as different  from a  common dementia.  Studies  since  the  1980’s  have,  however,
revealed specific  genetic and molecular mechanisms underlying AD pathogenesis
(Selkoe, 2002). Actually, AD is the most common form of dementia affecting about
18 millions persons worldwide. It is one of the major public health problems during
the  21st century  because  of  the  increasing  age  of  the  elderly  population.  The
incidence of the disease has been shown to rise sharply with age, from about 10% at
65 to 50% of the population at 85 (Heinz, 2002).
The two major histological features described originally are still characteristic for the
disease  namely:  extracellular  deposits  of  amyloid  (Aβ)  peptides  that  form  senile
amyloid  plaques  and  intraneuronal  neurofibrillary  tangles  (NFT)  comprising
phosphorylated forms of  microtubule-associated protein tau. Altered processing of
amyloid protein from its precursor APP is now recognized as the key event to the
pathogenesis of AD.
The pathogenesis of AD is generally divided into three stages (i) mild, (ii) moderate
and  (iii)  severe  according to  the  progression  of  symptoms:  (i)  in  the  first  stage,
patients show progressive loss of recent memory; (ii) moderately affected patients
display defective comprehension and orientation associated with hallucinations; (iii)
during  the  severe  stage,  patients  exhibit  very  limited  language capabilities,  daily
living behavioral  impairments  and increased aggressiveness.  Finally,  this  disorder
leads to death about 12 years after the first symptoms appear.
The complexity of the disease arises from the different risks factors that are involved
in the development of AD. The major risk factor is age. Ageing leads itself to neuron
loss and reduction of  synaptic  plasticity following injury including the capability  of
neurons to  support  long-term potentiation  (LTP)  processes  which are involved in
memory.
Other  risk  factors  have  been  described  and  help  in  the  characterization  of  AD
according to the age of the onset. For example, AD patients older than the age of 65
are considered to have late onset disease which accounts for more than 90% of all
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cases of AD with different additional risk factors such as: severe head trauma, low
level of education (Stern et al., 1994), increased alcohol consumption (Ruitenberg et
al.,2002),  depression as well as vascular factors (Kivipelto et al.,2001; Mayeux et
al.,2003) and female gender. Indeed, the incidence of disease is higher in women
probably because of their longer life expectancy and because of the postmenopausal
oestrogen  deficiency  suppressing  the  potential  of  plasticity  of  axons  (Bhavnani,
2003). 
In contrast, early onset familial AD (EOFAD) which accounts for less than 10% of all
AD cases is more related to genetic mutations such as (i) mutation of the Amyloid
Precursor Protein (APP) gene on chromosome 21. This APP gene locus has been
suggested to play a role in Down’s syndrome (trisomie 21). Studies have shown that
trisomic  patients  show  an  increased  risk  for  AD  caused  by  an  extra  copy  of
chromosome 21. (ii) Missense mutations of the Presenilin 1 and 2 (PS1and PS2)
genes,  respectively,  located  on  chromosomes  14  and  1,  seem  to  be  the  more
common  form  of  autosomal  dominant  AD  (Selkoe,  2001).  (iii)  Mutations  of  the
apolipoprotein E (Apo E) gene on chromosome 19. This cholesterol transport protein
has  commonly three  different  alleles  ε2,  ε3  and ε4  which encode three  different
isoforms of apolipoprotein E (E2, E3 and E4). The presence of allele ε 4 is the most
important genetic risk factor for AD. The mechanism whereby E4 promotes AD is not
understood, but there is evidence that E4 enhances Aβ aggregation and reduces Aβ
clearance.  ApoE  has  been  shown  to  be  associated  with  synaptosomes.
Synaptosomes deficient in ApoE appear to be more susceptible to oxidative stress.
Impairment  of  ApoE4  function  inhibits  neurite  outgrowth  and  dendritic  plasticity
triggered through a loss of neuron’s protection against oxidative stress (Lauterbach
et al., 2002).
In addition, AD has been characterized by the progressive degeneration of neurons,
particularly  cholinergic  neurons.  Loss  of  neurons  and  synapses  have  been
suggested  to  be  correlated  with  the  degree  of  dementia.  Based  on
neurodegenerative changes, a stage model of progression of the disease has been
proposed by Braak and coworkers starting in entorhinal  cortex, then extending to
limbic regions including hippocampus and finally to neocortex and the basal nucleus
of Meynert (Braak et al. 1995).
Actually, although molecular  and cellular  aspects of  the disease process are well
described, the early diagnosis of  AD by laboratory tests is still  unreliable.  Indeed,
there is a great clinical need for biomarkers to identify incipient AD in patients with
mild cognitive impairment. First, because some of the features or symptoms of AD
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can also be found in other disorders with memory impairment such as Parkinson’s or
Huntington’s disease. For this reason, all the disorders with similar symptoms must
be  excluded  by  differential  diagnosis  (National  Institute  of  Health).  At  present,
accurate diagnosis of AD cannot be done in the early stage of the disease and still
requires a confirmation in postmortem brain.  One possibility  to improve the early
onset-diagnosis of  AD would be to find biological  markers.  Early diagnosis of  AD
would help to initiate effective drug treatment (Frank et al., 2003) with the aim to slow
or to stop the degenerative processes (Blennow et al., 2003).
 
I.1.2-.    Pathophysiology 
Neurophathological changes
The brains of AD patients undergo many neuropathological changes associated with
decrease in language function, loss of memory, visuospatial process impairment and
cholinergic  neuron  loss.  Characteristic  morphological  changes  are  atrophy  of
parietal,  temporal and frontal cortex, basal forebrain system and hippocampus. In
AD, atrophy occurs early and progresses independently of the age of patients. An
index of brain atrophy has been described and was correlated with the severity of
cognitive impairment (Barber et al., 2001). Additional morphologic changes found in
AD brain include shrinkage of the gyri, thickening of leptomeninges and enlargement
of the ventricles as shown in Fig 1 (Barber et al., 2001).
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Fig  1:  Description  of  atrophy  that  can  be
visualized in AD brain (right) in comparison to
normal  brain  (left).  This  figure  shows  the
degeneration of basal forebrain and temporal
cortex  involved  in  memory  and  language
functionality
The two characteristic microscopic features of the disorder are senile plaques and
neurofibrillary  tangles  (NFT).  Seniles  plaques  are  nearly  spherical  extracellular
depositions as shown in Fig 2. They are generally found in the limbic system and in
association cortices (Selkoe, 2001).
NFT are abnormal fiber aggregations in the cell body and axons of neurons. They
are predominantly observed in the large pyramidal cells of the hippocampus, in the
entorhinal cortex, and in the granular layers of the associative cortices. In contrast,
primary sensory and motor cortices are relatively spared.
Senile Plaques, APP protein and Aβ
                                                                 
A fundamental  abnormality that  plays a key role  in the dysfunction and death  of
neurons  in  AD  is  altered  proteolytic  processing  of  APP  resulting  in  increased
production and accumulation in the brain of neurotoxic forms of Aβ. The evidence for
the amyloid hypothesis of AD is extensive and has been recently reviewed (Selkoe,
2002;  Mattson,  2004)  (Fig4).  Amyloid  plaques  are  caused  by  the  extracellular
deposits of β-amyloid protein (Aβ) that occur principally in a filamentous form. It has
been shown that these plaques appear in the early onset of the disease as diffuse
plaques and develop later into senile plaques with a dense core.
The  β  amyloid  peptides  are  formed  by  the  proteolytical  miscleavage  of  APP as
shown in  Fig  3.  APP is a  transmembrane  protein,  which has  an extracellular  N-
terminal  and  a  short  intracellular  C-terminal  domain. (Cognos,  2002).  APP  is
ubiquitously expressed in many human cells including CNS neurons. 
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Fig  2:  Left:  Normal  neurons,  Right:  Insoluble  amyloid β
aggregates  on  extracellular  part  of  neurons  and
neurofibrillary  tangles  composed  of  hyperphosphorylated
tau proteins deposits in neurons
Differential splicing of APP mRNA generates isoforms with different size (695,751
and 770 amino acids). The biological function of this protein is still unknown, but it
appears evident that APP contributes to neuroprotective effects such as formation
and maintenance of synapses, modulation of long-term potentiation (LTP) as well as
protection of neurons against oxidative stress.
APP can undergo a non amyloidogenic cleavage by α-secretase releasing a soluble
part sAPPα (Fig 3). Release of this soluble fragment from neurons can have a role in
neurite  outgrowth  and  functions  as  serine  protease  inhibitor  (Selkoe and  Shenk,
2003).  A  second cleavage by  γ-secretase can  generate  a small  p3 peptide.  The
identity  of  α-secretase  remains  unclear,  althrough  tumor  necrosis  factor  α-
convertase (TACE) (enzyme that cleave TNF receptor family at the cell surface) and
Adamalysin  family  of  proteins  (ADAM),  notably  ADAM 9  and  10,  are  candidates
(Allinson et al., 2003; Dewachter et al., 2002).
Amyloidogenic  cleavage  of  APP  within  the  Aβ domain  starts  by  β-secretase
cleavage, a  βAPP cleaving enzyme (BACE),  that  releases a soluble sAPPβ.  The
second part of this pathogenic cleavage is made by γ-secretases (Fig3). The identity
of  γ-secretases  remains  controversial  but  is  most  probably  composed  out  of  a
complex  of  4  membrane  proteins:  presenilin  1  (PS1)  and  its  close  homologue
presenilin 2 (PS2);  nicastrin;  aph-1 and pen-2 (Wolfe  et  al.,  2001;  Selkoe,  2001;
Kimberly et al.; 2003). Presenilins seem to be key mediators of the Notch signaling
pathway which is vital for cell fate decision during development (Selkoe, 2001).
Cleavage  of  APP  by  β-  and  γ-secretases  leads  to  formation  of  Aβ fragments
consisting of 39 to 43 amino acids. Two predominant Aβ peptides are present in the
senile plaques:  Aβ1-40 and Aβ1-42.  Aβ1-40 is more frequent  but  less toxic than
Aβ1-42 which aggregates more easily probably because of its longer size. Proteolytic
cleavage of APP can occur at different sites during its transport from endoplasmic
reticulum (ER) to the cell surface. These cleavage sites induce different fates for the
Aβ peptides.  The  proteolytic  cleavage  of  APP  into  ER  membrane  produces  a
significant amount of Aβ1-42 which is not secreted but remains inside the cell. In
contrast, when the cleavage occurs in the Golgi membrane, both Aβ1-40 and Aβ1-42
peptides are produced and secreted. Small amounts of Aβ occur at the cell surface
or in the lysosomal system (Wilson et al., 2003).
Aβ is a 4 kDa protein that aggregates first as dimer or trimer and condenses with
unfibrillar Aβ peptides to finally form the protofibrils present in diffuse plaques. Later,
Aβ1-40  starts  to  co-deposit  to  the  preexisting  Aβ1-42  deposits  (Selkoe,  2001).
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Diffuse plaques are the earliest detectable lesions in the AD brain and predate the
neuritic plaques. In addition, it has been shown that Aβ peptides accumulate in the
small  blood  vessels  of  meninges  and  cerebral  cortex.  The  contribution  of  this
accumulation  in  the  pathology  of  AD  is  at  present  unclear.  However,  clinical
complications due to cerebral hemorrhage are very rare in AD.
It remains uncertain whether diffuse plaques alone account for most of the neuronal
loss in AD since characteristic  amyloid plaques also  occur in  normal  aging brain
without memory disturbances.
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Fig 3: Physiological and pathological cleavage of amyloid
precursor protein (APP)
Tau protein and Neurofibrillary tangles
Many affected neurons in AD brains contain intracellular fibrillar aggregates of the
microtubule-associated protein tau that exhibit hyperphosphorylation and oxidative
modifications.  These  intraneuronal  cytoskeletal  filaments  (neurofibrillary  tangles;
NFT) are consistently found in AD in addition to senile plaques. NFT lesion can occur
independently  of  neuritic  plaques.  Tangles  composed  of  tau  aggregates
biochemically similar have been found in patients  without  dementia  as well  as in
diverse  neurodegenerative  disorders  such  as  Down’s  syndrome,  Pick’s  disease,
amyotrophic lateral sclerosis and Parkinson’s disease (Buee et al., 2000).
NFT have been found in the entire brain: during disease progression, the deposition
of NFT starts in the transentorhinal cortex, progresses to limbic regions particularly
hippocampus and eventually invades the neocortex.
NFT are formed by paired helical filaments (PHF) composed of hyperphosphorylated
tau  protein  (τ),  the  major  microtubule  associated  protein  (MAP).  In  the  human
organism,  tau  and proteins  of  the MAP family  are  found  in  neurons,  glia,  heart,
kidney, lung, muscles and fibroblasts. The human tau gene, located on chromosome
17, constitutes a family of  six different tau isoforms from 352 to 441 amino acids
generated  by alternative  splicing (Buee et  al.,  2000).  Much of  the  tau  protein  in
tangles is present in highly insoluble filaments. 
A variety of kinases have been shown to be capable of phosphorylating tau but it is
still  not  clear  whether  one  or  several  kinases  are  responsible  for
hyperphosphorylation initiation (Selkoe, 2001). In contrast, tau protein can be quickly
dephosphorylated  by  endogenous  phosphatases  such  as  Ser/Thr  phosphatase
protein 1, 2A, 2B and 2C. The degree of phosphorylation of tau crucially regulates its
biological activity. Phosphorylation of tau is of importance during development, for
cell  sorting  and  assembly  and  structural  stability  of  microtubules.  Healthy
microtubules are essential for the structure and function of neuronal cells (Cognos,
2002).   Tau hyperphosphorylation in AD leads to aggregation in the neuronal cell
body and axons and finally to impairment of synaptic transmission. Aggregation of
NFT is associated with increased neuronal degeneration in AD (Ramirez-Chamond
et al., 1999). Programmed cell death clearly occurs in neurodegenerative disorders,
it remains, however, uncertain whether it accounts for the most of the neuronal loss
in AD. Appearance of an aberrant cell cycle has been proven in AD and appears to
have a particular role in the CNS neurodegeneration (Hamdane et al., 2003). 
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The Aβ hypothesis
Hallmarks of AD are Aβ deposits and tangle formation. Further studies proved that
mutations  of  PS1  and  PS2,  ApoE  4  and  APP  are  involved  in  AD  pathology.
Currently, the idea that Aβ accumulation is the first event in AD (as shown in Fig 4)
and that the following processes such as tau-tangle formation or inflammation result
from a primary imbalance between  Aβ production  and Aβ clearance  is  generally
accepted (Hardy and Selkoe, 2002).
Inflammation  is  included  in  this  pathogenic  cascade  as  Aβ  fibrils  are  intimately
surrounded  by dystrophic  axons and dendrites,  reactive  astrocytes  and  activated
microglia.  This  key  role  of  chronic  inflammation  in  AD is  now accepted,  but  the
mechanisms  involved  in  neuronal  death  and  synaptic  failure  are  still  under
discussion.
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Fig 4:  Representation of the Aβ hypothesis
I.2- INFLAMMATION
I.2.1- Inflammation in Alzheimer’s disease
Generally,  inflammatory  processes  appear  after  diverse insults  including  invading
microbes  such  as  viruses  and  bacteria  as  well  as  injurious  chemicals,  physical
insults,  immune mechanisms, hypoxia,  stress, age and tissue damage in order to
keep a normal balance in organism homeostasis (Wyss-Coray et al., 2002). 
The role of inflammation in the CNS is still unclear and the mechanisms of action of
this  immune  response  have  been  deduced  from  what  is  known  in  autoimmune
disorders.
Involvement of inflammation in the CNS and particularly in AD has been for a long
time unknown or underestimated. The principle ideas were based on the fact that the
brain has a protection system against attacks, the blood brain barrier (BBB). In auto-
immune diseases or stroke, the BBB is breached and inflammation in the CNS was
then described as adaptative immune response triggered by invasion of lymphocytes
or monocytes into the brain in order to detect and reduce the injury (Mc Geer et al.,
2003). In contrast, the BBB in AD was never found breached and for this reason the
view had to be extended. Finally it has been shown that the inflammation in AD brain
is an innate immune response with activation of  glia cells including microglia and
astrocytes (Akiyama et al., 2000). The role of astrocytes and microglia cells in AD
has been postulated since decades. They were thought to be involved primarily in
removal of Aβ deposits by phagocytosis. Finally, it has been shown that microglia
cells are actively involved in the inflammatory response triggered by Aβ (Meda et al.,
2001).
Increasing experimental evidence indicates that inflammation significantly contributes
to AD pathogenesis: First, amyloid plaque deposition in the AD brain leads to local
inflammation  by  permanent  activation  of  microglia.  Second,  the accumulation  of
activated  microglia  cells  occurs  close  to  the  senile  plaques.  Even  if
neuroinflammation is not considered as the primary event in the development of AD,
the activation of these brain specific macrophages has been described as an early
event  in  the  developing  disease  (Vehmas  et  al.,  2003). Reactive  astroglia  that
surround senile plaques release inflammatory mediators and effectors to orchestrate
defense mechanisms and to initiate the removal of the pathogenic trigger molecules
(Liu et al 2003). Indeed, numerous markers of inflammation have been found in AD
brain: (i) accumulation of proinflammatory cytokines such as TNF-α, IL1-β, or IL-6
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released  by  activated  microglia  cells  and  astrocytes;  (ii)  strong  activation  of  the
complement system; (iii) increased oxidative stress with uncrontrolled production of
highly reactive oxygen radicals contribute to the lesions in AD brain.
Whether  activation  of  microglia  and  astrocytes  can  either  promote  or  counteract
neurodegenerative processes is still unclear (Rogers et al., 2002). Activation of glia
should help to eliminate the invaders but there may be a risk of misdirection of the
immune reaction that can initiate autoimmune responses against host proteins. 
This disregulation can lead to the production of an autotoxic loop as shown in Fig 5
(Mc Geer et al., 2002). 
Risk factors
Gene mutations, Ageing
Environment and others
Disease
Senile plaques, neurofibrillary
Tangles Autotoxic loop
Cytokines and complement
Neuronal death
Microglia recruitment
Complement activation
cytokines
Because all the mechanisms involved in AD can play an opposite role, the immune
response can be of benefit in CNS injury and these events could possibly lead to a
future immunotherapy for  AD (Monsonego et al.,  2003).  Actually, the most recent
studied therapeutic intervention is vaccination with Aβ (Selkoe, 2002). 
I.2.2- Complement activation in Alzheimer’s disease
Activation  of  the  complement  pathway  is  an  essential  part  of  the  inflammatory
response and is deeply implicated in autodestruction of neurons. Activation of the
complement system destroys invaders and helps their elimination by phagocytosis.
In AD, aggregated Aβ has been shown to be a strong complement activator (Rogers
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Fig 5 : Autotoxic loop of the central
nervous system degeneration
et al., 1992). Activation of the complement system by the classical pathway with C1q
binding, and the alternative pathway has been supposed to exacerbate the pathology
of AD suggesting that complement inhibitors could be used as potential therapeutic
agents (McGeer and McGeer, 2001, 2003). Both classical and alternative pathways
lead to the formation of protease complexes that can easily be detected by microglia
or phagocytic receptors in order to be removed (McGeer et al., 2002; Farkas, 2003).
The complement system has to be precisely regulated in order to protect cells from
abnormal activation. An inhibitor of complement activation has been found in mice:
complement receptor-related protein y (Crry). Studies on transgenic mice expressing
a  human  APP  mutation  and  soluble  Crry  (sCrry)  have  shown  an  increase  in
extracellular  deposition  of  Aβ  peptides  and  reduced  activation  of  microglia.  This
points to a neuroprotective role of complement in Aβ induced neurodegeneration and
clearance of  amyloid.  However,  these findings do not exclude the possibility  that
complement  activation in neurodegenerative  conditions  may also have neurotoxic
consequences (Wyss-Coray et al., 2002).
I.2.3- Cytokine pathways
Cytokines are a heterogenous group of small molecules that can participate to innate
or acquired immunity in an autocrine or paracrine fashion. Cytokines are secreted
and released by activated microglia cells after injury. These proteins can have pro- or
anti- inflammatory activities. Some of the cytokines have been suggested to have an
impact  in  AD  such  as  TNF-α,  IL1-β,  and  IL-6  which  have  been  detected  as
overexpressed proteins in AD brains.
IL-1 is an immunoregulatory cytokine and its expression is increased in the early
phase of the plaque formation. IL-1 exerts a direct action on the formation of senile
plaques  via  an  upregulation  of  βAPP  and  a  stimulation  of  its  processing
(Neuroinflammation Working Group, 2000).
IL-6  is  a  pleiotrophic  cytokine  that  can  mediate  various  processes  in  the  CNS
including cell growth and differentiation. IL-6 is produced and expressed at low levels
in normal adult CNS but is strongly induced under pathological conditions (Vanden
Berghe et al., 2000). IL-6 can be produced by microglia cells, astrocytes, neurons
and  endothelial  cells.  Its  overexpression  is  generally  associated  with  detrimental
effects.  Moreover,  IL-6  may  have  anti-inflammatory,  immunosuppressive  and
neuroprotective  actions  probably  via  neurotrophins  such  as  Nerve  growth  factor
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(NGF)  actions  (Tarkowski,  2002).  Because  of  its  polymorphism,  IL-6  has  been
described as a genetic factor for AD (Papassotiropoulos et al., 2001).
TNF-α appears to have completely opposite actions in AD: normal levels of TNF-α
have  been  reported  to  have  a  beneficial  effect  on  hippocampal  neurons  of  rats
whereas  overexpression  of  this cytokine resulted  in human cortical  neuron death
(Perry et al., 2001).
I.2.4- Oxidative stress in Alzheimer’s disease
Increased oxidative stress (enhanced production of highly reactive oxygen radicals)
can  be  triggered  by  several  stimuli.  First,  ageing  is  a  condition  of  increased
production of free radicals. In addition, inflammatory responses have been shown to
initiate oxidative stress. 
A  key molecule in oxidative stress is nitric oxide (NO). NO produced from L-arginine
is a diffusible free radical with multiple functions in mammalian cells. NO is produced
by NO synthase (NOS). There are 3 different NOS including neuronal (nNOS) and
endothelial  (eNOS)  enzymes,  both  expressed  constitutively,  as  well  as  inducible
NOS (iNOS). Induction of iNOS can produce high levels of NO which is known to be
a  component  of  nonspecific  immune  responses.  The  biological  fate  of  NO  is
influenced by its own concentration and the surrounding conditions such as pH, CO2
concentration or redox state (Boje, 2004).
NO is  highly  reactive  to  other  oxygen components  and  formes  easily  neurotoxic
effectors  with  reactive  oxygen  species  (ROS)  including  superoxide  anion  O2.-,
hydrogen peroxide H2O2 and hydroxylyl radicals OH. resulting in reactive nitrogen
species (RNS) such as peroxynitrite anion ONOO- which finally causes cell death by
inducing DNA damage protein oxidation and nitration. 
NO has two different kinds of interaction: (i) oxidation not involving attachment of NO
groups to target molecules. These oxidations lead the formation of modified proteins
with loss of function which then affect multiple homeostatic mechanisms in the brain.
(ii) covalent modifications of proteins notably S- or N- nitrosylation: tyrosine is more
often  nitrated  than  the  two  other  aromatic  amino  acids,  tryptophane  and
phenylalanine,  because  of  its  mild  hydrophobicity  and  its  surface  localization  in
proteins  (Ischiropoulos,  2003).  The  most  toxic  mechanism of  NO is  the  reaction
between NO. and superoxide O.2-  that produces peroxynitrite anion ONOO-. 
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This  reaction  has  pathophysiological  consequences  including  DNA damage,  lipid
oxidation  and  protein  modifications  via  formation  of  3-nitro  tyrosine  (Jiao  et  al.,
2001). 
Interestingly,  NO  can  also  function  as  a  protective  antioxidant  at  physiological
concentrations. Physiological levels of NO influence synaptic efficacy by regulating
neurotransmitter release. In contrast,  excess of NO causes excitotoxic brain injury
(Meda et al. 2001). Moreover, NO which is produced by certain CNS cells can elicit
neurotoxic effects on the same cells: e.g neurons, astrocytes, activated microglia or
endothelial cells (Boje, 2004).
Oxidative  stress  in  neuroinflammation  has  been  shown  to  contribute  to  various
neurodegenerative  diseases  such  as  Amyotrophic  Lateral  Sclerosis,  Huntington’s
disease or AD. Even if  it is not a primary event, oxidative stress seems to appear
very early in AD pathogenesis (Nunomura., 2001).
Overexpression of NO (Monsonego et al., 2003) and presence of proteins containing
3-nitrotyrosine  have  been  shown  in  several  inflammatory  diseases,  cancer  and
neurological disorders including AD (Pignatelli  et al., 2001). Aberrant expression of
the three NOS isoforms has been found in different cell types of the AD brain and
was associated with high level of colocalized nitrotyrosine (Lüth et al.,  2002).  The
respiratory  system of  activated  microglia  is  involved  in  free  radical  attack  of  AD
brains via the production of oxygen free radicals. 
Treatment with drugs interfering with NO and oxidative stress may be used as new
therapeutic approaches of AD. For example, an antioxidant substrate like X34 has
been shown to bind to Aβ deposits and to decrease oxidative stress related to Aβ
deposition in synaptosomal and hippocampal neurons (Kanski  et al., 2003).
I.2.5-  Synaptic failure in Alzheimer’s disease
Presence of neuritic plaques and NFT in the septal region of hippocampus and basal
forebrain neocortex leads to the destruction particularly of cholinergic neurons of the
basal  forebrain  in  AD  brain.  The  deficits  in  cholinergic  transmission  are  early
symptoms for the disease. For these reasons, AD has been suggested to be first
triggered  by  a  specific  impairment  of  synaptic  transmission  (Small  et  al.,  2001;
Selkoe, 2002).
It  was first  presumed that  neurotoxicity of  Aβ is  mediated  by changes in  cellular
calcium signaling but recent data demonstrate that Aβ directly interacts with neuronal
membranes (Yamaguchi et al., 2000). Aβ peptide induces ultrastructural changes in
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synaptosomes  (Mungarro-Menchaca  et  al.,  2002).  Then,  according  to  the  Aβ
hypothesis, deficits in synaptic transmission such as LTP occur a long time before
Aβ deposits become detectable (Selkoe, 2002).
Initiation  of  the  neurodegenerative  cascade  has  been  hypothesized  to  occur  in
synapses and, in fact, the loss of the synaptic-associated protein synaptophysin has
been suggested as an early marker of neurodegeneration (Mungarro-Menchaca et
al., 2002).
Moreover, the oxidation that occurs in AD brain triggered by amyloid β peptide leads
to lipid peroxidation of different membranes (Lauderback et al, 2001; Butterfield et
al.,  2002).  Lauderback  et  al.  (2002) have  shown  that  ApoE  is  associated  with
synaptosomes.  Moreover,  deficient  synaptosomes are  more  susceptible  to  a  Aβ-
induced oxidation suggesting a specific antioxidant role for ApoE.                  
III.3- PROTEOMIC TECHNOLOGY
Proteomic analysis aims the high throughput analysis of total proteins expressed in
an  organism  (proteome).  Then,  it  provides  valuable  informations  about  the
expression level of proteins and post translational modifications, as well as changes
of  these parameters due to diseases or external  factors.  It  is  a recent  techology
already  routinely  used  for  clinical  diagnosis  and  for  investigation  of  infectious
diseases,  cancer  or  neurological  disorders  (Fountoulakis,  2001).  A  proteomic
analysis  comprises  two  major  steps :  separation  of  the  protein  mixture  and
identification of these separated proteins by mass-spectrometry. 
As  every  technology,  proteomic  analysis  has  some  limits:  i.e  the  detection  of
hydrophobic  or membrane proteins is  difficult  due  to  their  low solubility.  Proteins
have  to  be  brought  and  kept  in  solution  during  the  whole  process  of  proteomic
analysis for an efficient detection. Another limiting factor is the size of proteins, e.g.
proteins  smaller  than  10  KDa  or  bigger  than  120KDa  are  rarely  detected
(Fountoulakis, 2004). 
Despite  these  draw-backs,  the  technology  has  been  proven  to  be  powerful  for
studing changes in bacterial  proteome or in various cell lines.  Analysis of  tissues
such as brain is actually possible but is difficult due to the involvement of multiple
factors: sex, age, and medical treatment for human samples (Fountoulakis, 2001).
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A major advantage to use proteomics instead of other analytical techniques is that
with the development of mass-spectrometry, automation and availability of informatic
software this technique allows the analysis of large amounts of informations. 
This  new  technology  was  used  and  improved  depending  on  the  specific
requirements for this study. 
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AIM OF PROJECT
Aim of this study was 
(i) To prove the involvement of inflammation in AD pathogenesis with the final goal to
identify markers for the early onset-stages of this disorder. 
(ii) To identify and characterize proteins involved in AD inflammation using defined
cell culture systems. The results obtained in vitro will be compared with an APP/PS2
transgenic mouse model for human AD and with post-mortem human AD brain. 
(iii) To monitor tyrosine nitrated proteins in the transgenic mouse model. 
(iv) To establish a detailed map of cytosolic proteins in mouse brain. 
(v) To isolate synaptosomes of brain with the goal of mapping synaptic membranes.
For these studies, proteomic technologies such as Matrix assisted laser desorption
ionization (MALDI) coupled with time of  flight  (TOF) analyzer were used.  Internal
softwares programs from F Hoffmann-La Roche AG were available to analyse data.
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II- MATERIALS AND METHODS
II.1- MATERIAL
II.1.1- Material
Dulbecco′s modified Eagle′s medium (DMEM), William E medium, fetal calf serum
(FCS) and other cell culture supplements were purchased from GibcoBRL (Basel,
Switzerland).
Immobiline dry strips (pH 3-10; Non linear; 18 cm) were purchased from Amersham
Pharmacia Biotechnology (Düdendorf,  Switzerland).  ZOOM IPG-strips (pH 3-10 or
pH 4-7; 7cm) for the ZOOM IPG-runner system, were obtained from Invitrogen life
technologies.
Hybond ECL nitrocellulose membranes used for Western blotting were purchased
from Amersham Pharmacia Biotech.
Acrylamide was obtained from Serva (Wallisellen, Switzerland) and the reagents for
the SDS-PAGE were purchased from Bio-Rad laboratories (Reinach, Switzerland).
Carrier  ampholytes  (resolyte  3.5-10)  were  bought  by  BDH  Laboratory  Supplies
(Poole,  UK).  CHAPS,  Thiourea  and  Iodoacetamine  were  from  Sigma  (Buchs,
Switzerland), Urea and Dithioerythreitol (DTE) were obtained from Merck (Dietikon,
Switzerland). Trypsin was first obtained from Promega (Wallisellen, Switzerland) and
then directly from F. Hoffmann- La Roche (Basel, Switzerland).
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II.2 METHODS
II.2.1- Cell culture and treatment
The human microglia cell  line (hMC-3) (Janabi et al.,  1995) was grown in DMEM
containing 10% FCS, 2% Penicillin-streptomycin and incubated at 37°C in humidified
atmosphere  containing  10%  CO2.   Prior  to  stimulation,  cells  were  washed  with
phosphate buffered saline (PBS) and preincubated in William’s E medium without
FCS for 2 hours. For stimulation, cells were either untreated or incubated with 1nM
human Interleukin 1 (IL-1) plus 1nM Tumor necrosis factor –α (TNFα) for 24 hours in
William‘s  E  medium.  Subsequently,  the  cells  were  harvested  in  mannitol  buffer
(0.29M mannitol, 10 mM triethylamine, 10mM acetic acid, 1mM EDTA and protease
inhibitor (Boehringer-Mannheim, Germany) and centrifuged for 2 min at 200 xg at 4°
C.  Thereafter  the  pellet  was  resuspended  in  1  ml  mannitol  buffer  and  lysed  by
homogenization  in  a  douncer  homogenizer  (20  strokes).  The  extract  was further
purified  by  differential  centrifugation,  first  at  750xg  for  15  min  at  4°C,  then  the
supernatant or cytosol purification was followed by at 15’000xg for 20min at 4°C and
50’000xg for 30 min at 4°C.
II.2.2- Transgenic  animal model
The  following  transgenic  (tg)  mouse  model  APP/PS2  (generated  by  Dr  Ozmen
Laurence, PRBD, Roche, Basel) was used:
- overexpression of a cDNA carrying the Swedish double mutation K570N, M671L of
human APP under Thy 1 neuron specific promoter.
- overexpression of a cDNA carrying the mutation N141I of human PS2 under prion
promoter.
The  most  important  pathological  characteristic  feature  of  these  mice  is  the
accelerated development of fibrillar Aβ deposits in cerebral cortex and hippocampus
as  compared  to  APP  tg  mice.  Behavioral  studies  of  the  transgenes  revealed
significant changes in cognitive functions in the early phase of the disease long time
before plaque formation occurs.
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II.2.3- Protein determination with Bradford method
A Bio-Rad protein  microassay,  adapted  from the Bradford  dye-binding procedure
(Bradford., 1976.), was used in order to determine low concentrations of proteins.
The  standard  curve  was  achieved  with  BSA  standards  at  the  concentration  of:
1.5mg/ml;  1mg/ml;  750  µg/ml;  500  µg/ml;  250  µg/ml;  125µg/ml;  25  µg/ml  and  5
µg/ml. 
25 µl of each standard was mixed with 1 ml of Bio-Rad protein assay solution diluted
1 to 5 times. The same dilution with the Bio-Rad dye was made for the samples.
Measurement  of  the  color  change  of  Coomassie  Brilliant  Blue  G  250  dye  was
performed at 595λ using a Microtiterplate scanning spectrophotometer Power Wave
200 from Bio-Tek Instruments.
II.2.4- Western blot analysis
Samples were merged with NuPAGE sample buffer containing 50mM DTE at a final
concentration. The mixture was boiled at 95 °C, loaded on 4-20% Tris-Glycine gels
or on  4-12% NuPAGE gel, run first at 75V for half an hour and then at 130V for 2
hours.
For the transfer of proteins from SDS gels to nitrocellulose membrane, a semi-dry
transfer  cell  chamber  (Bio-Rad)  was  used.  First,  6  Whatman  papers  and  1
nitrocellulose membrane were moistened in transfer buffer. For one gel, the packing
into the apparatus consisted out of 3 Whatman papers, then the membrane, followed
by the gel and 3 Whatman papers. Transfer buffer was either Towbin buffer (191mM
Glycin; 25mM Tris and 20% (v/v) Methanol) for Tris-Glycine SDS gels or NuPAGE
transfer buffer from Invitrogen.
Blotting ** was achieved at 20V for 70 min. In order to detect any transfer artefacts,
membranes  were  quickly  stained  with  Ponceau  S  from  Sigma.Then  membranes
were blocked with Superblock blocking buffer from Pierce Biotechnology for 30 min.
Unspecific binding sites of the membranes for antibodies were blocked by addition of
5% Milk T-PBS (non fat dry milk, BIO-RAD and 0.1% Tween-PBS). The membrane
was quickly washed with T-PBS. The first antibody was left overnight on membranes
in 0.5%milk, T-PBS.  Membranes were then washed 2 times quickly and 2 times for
5 minutes  with  T-PBS.  Thereafter,  the  second  antibody in 0.5%milk,  T-PBS was
added for a minimum 2 h. Dilution of  the antibodies depended on the antibodies
used. Membrane was washed again 2 times quickly and 2 times for 5 minutes with T-
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PBS.  Detection  of  Antibodies  was  performed  with  Lumi-light  Western  blotting
substrate from Roche Diagnostic Corp. The maximal incubation time of this substrate
on membranes amounted to 5 min.
** Western blot analysis of criterion gels for nitrated proteins. For this particular case,
the gels were pre-equilibrated after the second dimension with Towbin buffer for a
minimum of 1 hour and a wet transfer was achieved. Transfer  was performed at
100V during 2 hours in Bio-Rad criterion cassette with nitrocellulose membranes into
Tris Glycine SDS buffer (25 mM Tris, 192 mM Glycine, 0.1% w/v SDS and pH 8.3).
II.2.5- Co-Immunoprecipitation
Dialysis  of  3  mg  of  protein  from  mice  brain  cytosol  extract  against  Ripa  buffer
containing 150 mM NaCl, 1% Nonidet P-40, 0.5% Deoxycholate, 0.1% SDS, 50mM
Tris  pH  8  plus  proteases  inhibitors  was  done  overnight  at  4  °C.  Dialysis  was
performed in  Slide-A-Lyser  3.5K dialysis cassettes  from Pierce.  These are 3,500
MWCO cassettes with a maximum capacity of 0.5 ml.
The samples were divided into equal portions and diluted up to 500 μl total volume
with Ripa buffer. Each portion contains about 300 mg of protein. To each tube an
appropriate  concentration  of  antibody was added.  The incubation of  the antibody
was left overnight on a wheel at 4°C.
Equal  amounts  of  protein  A and  protein  G Sepharose  were  mixed in  PBS.  This
mixture was washed 5 times with 5 volumes of PBS and 1 time with 2 volumes of
Ripa buffer. Finally 1 volume of Ripa buffer was added to this mixture.
50 μl  of  the 1:1 slurry preparation of  protein  A/G Sepharose in Ripa buffer,  was
added to  each 500 μl  portion  samples and incubated 2 hours  at  4°C.  Incubated
samples were washed 6 times with 5 volumes of PBS before 1 volume of NuPAGE
sample buffer was added. This preparation can then be loaded on a gel and run as
described before.
II.2.6- Purification of aldolase C with a size-exclusion column
In order to isolate aldolase C from the cytosolic fraction of mice brain extract, a high
performance liquid chromatography (HPLC) analysis was performed.
A size exclusion column Superose 6HR 10/30 from Amersham Pharmacia Biotech
was used to enrich and purify the protein. The column was first washed with Milli-Q
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water. Further equilibration was done with two column volumes of 320mM Sucrose,
5mM Hepes, pH 7.4 buffer.  All buffers were prefiltered before use. The maximum
capacity of the column is 5 mg of proteins in 240 μl total volume.
The sample was loaded on the column at a flow rate of 0.3 ml/min. 1ml fractions
were collected and fractions containing the aldolase C were detected by Western
blot analysis. The apparatus used for this purpose is an AKTA prime from Amersham
Biosciences.
II.2.7- Homogenisation of total mouse brain and cortex
After dissection of the brain, total brain or specific brain regions such as cortex were
frozen  in  liquid  nitrogen.  The  samples  were  homogenised  using  a  motor-driven
pestle and then resuspended in 1 ml of 50mM Tris pH8, 1%NP40, 1mM MgCl2, 5mM
EGTA, 5mM DTT; 100mM NaCl plus protease inhibitor. The samples were further
sonicated 20 times at level 9 and 20-30cycles. A centrifugation step was applied at
50000xg for 30 min at 4 °C and the resulting supernatant used for 2D gel analysis.
II.2.8- Synaptosome extraction protocol (Gordon-Weeks et al. 1987;
Huttner et al. 1983)
Mice C57Bl/6J were killed by decapitation and brains were softly homogenized with a
glass  tube  potter  (12  times  up  and  down  at  800  rpm)  in  a  cold  room  4°C.
Homogenization was done in buffer A: 320 mM sucrose 5 mM Hepes buffer pH7.4
(0.1% w/v).
The extract was purified by differential centrifugation, first at 800xg for 10 min at 4°C.
The supernatant was further centrifugated at 10000xg for 15min at 4°C. The pellet
was resuspended in 10ml of buffer A and centrifuged again at 10000xg for 15min at
4°C. The resulting pellet was resuspended in 2 ml of buffer A and merged with 6 ml
of 8.5% Percoll. The Percoll gradient ranges from the bottom of the tube: (i) 4 ml of
16% Percoll; (ii) 3 ml of 10% Percoll and (iii) 6 ml of the probe mixtures was applied
to the top of the gradient. Gradient centrifugation was performed at 15000xg at 4°C
for 1h30 with a swing-out rotor. The crude synaptosomal fraction was localized in the
interphase between 16% and 10 % and was diluted 1:1 with isotonic Krebs buffer (20
mM Hepes,  10 mM Glucose, 145 mM NaCl, 5 mM KCl,  1.2 mM CaCl2,  1.3 mM
MgCl2, and 1.2 mM NaH2PO4) and re-centrifuged at 72000 xg for 1 h at 4°C.
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The pellet was resuspended in 1 ml of 5mM Tris-HCl pH 8.1, dounced 6 times with a
1 ml homogenisator and left on ice for 30 min in order to lyse the synaptosomes.
After lysis, 1ml of isotonic Krebs buffer with 5 mM additional NaCl was added to the
lysed sample. This mixture was then centrifuged at 25000xg for 20 min at 4°C and
the supernatant further purified at 200000xg for 2 h at 4°C. These two centrifugation
steps  lead  to  the  separation  of  synaptic  organelles  in  the  supernatant  (S3)  and
synaptic  membranes in pellet  (P3)  and finally  to  separation  of  the  synaptosomal
vesicle membranes (P4) and their cytosol (S4).
II.2.9- Proteomic analysis
 Sample preparation
Soluble protein extracts obtained were mixed with equal volume of IEF sample buffer
(Urea 7M, Thiourea 2M, 50 mM Tris-HCl pH7.5, 2 %( w/v) CHAPS, 0.4 %( w/v) DTE,
0.5 %( v/v) resolyte and traces of bromophenol blue) and concentrated in centrifugal
filter tubes  (Millipore corporation, Volketswil, Switzerland) at 2’000xg, 4°C for 20 min.
This procedure was repeated three times. Protein concentration was determined by
the Bradford method (1). 
Gel  strips  were  rehydrated  overnight  by placing them side-down in  a  immobiline
DryStrip  Reswelling  Tray  (Amersham  Pharmacia  Biotech.)  containing  rehydration
buffer (8M Urea, 2%(w/v), CHAPS, 0.4 %(w/v), DTE. 0.5 %(v/v), resolyte and traces
of bromophenol blue) covered with paraffin oil.
 Two dimensional (2D-) gel electrophoresis
Total soluble protein amounts of 1mg were applied on 18 cm IPG-strip and were
subjected  to  isoelectric  focusing.  The  focusing  program  with  the  IPG  phor  cup
loading  system (Amersham Pharmacia  Biotechnology)  is  composed of  five  steps
including: (i) start at 300 V for 3h; (ii), a step from 300V to 600V for 4 h; (iii), a step
from 600 V to 1000V for 5h, and (iv), a step from 1000V to 8000V for 3 h, and finally,
at 8000V for 3 h.
Prior to second dimension electrophoresis,  IPG gel strips were equilibrated for 15
min in a reducing solution (6M Urea, 50mM Tris-HCl pH8.8, 30% Glycerol, 2% SDS,
0.03 M Dithioerythreitol) followed, for 15 min in a alkylation solution (6M Urea, 50mM
Tris-HCl  pH8.8,  30%  Glycerol,  2%  SDS,  0.23M  Iodoacetamine).  The  second
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dimension  separation  was  carried  out  in  a  Protean  MultiCell  (160×299×1.5mm)
system (Bio-Rad) for  6 h at  40 mA per gel in a solution of  25mM Tris,  192 mM
Glycine and 0.1% (w/v) SDS.
Gel staining, imaging and protein digestion
The  protein  content  of  the  gel  was  determined  by  the  Coomassie  blue  method
(mixture  done  according  to  the  kit)  (Novex,  Invitrogen,  Basel,  Switzerland).
Coomassie  blue-stained  gels  were  destained  in  water  and  scanned  in  an  Agfa
DUOSCAN  densitometer.  Electronic  images  of  the  gels  were  recorded  using
photoshop  software  (Adobe).  Then,  a  software  program  Fragment  21  and  later
Scimagic were used to identify and save the coordinates of  the visible spots. The
corresponding  spots  were  automatically  cut  out  using  an  automated  gelpicker
(Sisyphus, Roche, Basel). 
Picked spots were placed into 96-well  microtiter  plates,  destained with a solution
containing 50mM Ammonium hydrogen carbonate and 30% Acetonitril,  and finally
dried  in  speedvac  evaporator  for  20  minutes.  Digestion  of  the  proteins  was
performed overnight with 5µl/spot with aqueous trypsin (15µg/ml) solution at room
temperature.
Matrix assisted laser desorption ionization- mass spectroscopy (MALDI-MS)
After digestion, 20 µl of a solution containing 50% Acetonitrile, 0.1% Trifluoroacetic
acid  (TFA)  was  added  to  each  spot  and  the  samples  were  incubated  at  room
temperature for 15 min.
The Bruker target was washed previously with deionised water and then sonicated
for  10  minutes  with  absolute  ethanol.  The  sample  application  onto  targets  was
performed by a Cybio apparatus (Roche, Basel). The robot applied simultaneously
1.5µl of the sample mixture and 1µl of matrix, consisting of 0.25mg/ml α-Cyano-4-
hydroxycinnamic acid (Sigma) in buffer containing65% Ethanol, 32% Acetonitrile and
0.03% TFA.
Two  standards  were  added  to  the  matrix  for  an  internal  calibration  of  the  MS:
Bradykinin (10pmol/µl) (FW 904.4681) and ACTH (41pmol/µl) (FW 2465.1989).  
After  drying  of  the  loaded  targets  at  room  temperature  in  darkness,  they  were
transferred for 10 minutes to 4°C. Then a recristallisation step was performed with
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the  same robot  which  applied  0.8µl  of  a  recristallisation  solution  containing 65%
Ethanol, 32% Acetonitrile and 0.03% TFA solution. At the end, we spotted by hand
onto the target: 1.5µl of human serum albumin (100pmol) in 1µl of 5mg/ml matrix, to
calibrate the apparatus.
Samples were analyzed in a time-of-  flight  mass spectrometer (Ultraflex,  Bruker).
Samples and matrix were submitted to a laser ray. The time of flight of the peptides
after laser shots is correlated with the mass of the peptide which are represented by
a  spectrum  related  to  the  peptide  mass  fingerprinting  of  the  global  protein.  The
peptide masses were compared to the theoretical peptide masses of all available
proteins databases from all species (see: Westermeier R. Proteomics in practices,
2002).
Description of  MALDI/TOF
A mass spectrometer is composed out of an ion source which is the matrix, a mass
analyzer which is a TOF analyzer that separates ions according to the mass charge
ratio (m/z) and a detector that delivers a mass spectrum. The laser employed is a
N2-laser operating at a wavelength of 337 nm with pulse durations of 1-5 ns. Shots
of laser into matrix and sample create a beam of gaseous ions which are accelerated
from sample to analyzer. Then the time between acceleration and detection of ions
on the  detector  is  measured  by the  analyzer.  Detectors  used  are  micro-channel
plates which are porous solid cores containing millions of tiny holes (ø 5-10μm and
0.5-0.8mm  length)  and  play  a  role  as  multiplier.  Finally,  micro-channel  plate
detectors delivered voltage outputs which have to be digitized and sent to a PC for
analysis.  
The machine used were first Autoflex with a sensitivity of 2-3 femtomol and later the
Ultraflex system which has a sensitivity of 100 attomol, both in a total mass range of
5000 Da (Bruker Daltonics. 2002).
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II.2.10- Miniaturization of all proteomic  technologies
Invitrogen ZOOM IPG runner system
Minisystem (Invitrogen Life Technologies) was first  used in order  to  minimize the
quantity of protein consumption which has to be applied in the first electrophoresis
dimension (60 to 90 µg used instead of 500 µg to 1 mg). Another advantage is the
facility of handling and the time of processing.
Desalting of samples is a key event and final salt concentration should be less than 
5mM.  The  desalting  column  used  for  this  purpose  is  the  Micro  BioSpin  6
Chromatography  Column  from  Bio-Rad.  The  column  had  to  be  equilibrated  with
500µl of the IEF sample buffer followed by centrifugation at 1000 xg for 1 min. This
was repeated 3 times. Sample was applied on the column, centrifuged for 4 min at
1000 xg. The eluate collected at the end contains the desalted samples.
 7cm ZOOM IPG strips  (pH3-10)  from Invitrogen were placed  overnight  at  room
temperature into a ZOOM IPG runner cassette (Invitrogen) with gel-side up. The total
volume  applied  on  these  strips  (sample  +  rehydration  buffer)  is  155µl.  To  limit
evaporation, two papers were placed on the two entries of the cassette limited by
white plastic. After overnight rehydration, the strips were left in the cassette and only
the two white plastic were removed and replaced by 2 absorbant papers: one was
moistened with a diluted 1: 200 cathode buffer (stock solution kept at 4°C) and the
other  with  175X  dilution  of  anode  buffer  (stock  solution  kept  at  RT).  Then,  the
cassette  is  placed  into  a  mini-cell  chamber  filled  with  650  ml  of  Milli-Q  water
(according  to  Invitrogen  protocols).  The  isoelectric  focusing  was  done  with  an
Electrophoresis  Power  Supply  EPS  3501XL  from  Amersham  Bioscience.  The
program on the Mini system is composed of four steps including: (i) start at 200 V for
20 min; (ii), then at 450V for 15 min; (iii), then  750V  for 15 min, and finally (iv), a
step at 2000V for 2 hours.
After focusing, strips were equilibrated for 15 min in a reducing solution (6M Urea,
50mM Tris-HCl pH8.8, 30% Glycerol, 2% SDS, 0.03 M Dithioerytheitol) followed, for
15 min by an alkylation solution (6M Urea, 50mM Tris-HCl pH8.8, 30% Glycerol, 2%
SDS, 0.23M Iodoacetamine).
The second dimension was performed into “X-cell sure lock chamber” from Novex
with  ZOOM gels 4-12% NuPAGE with  MES buffer.  Then the  gel  can be directly
stained with Coomassie blue and spots can be picked (as described before).
Biorad minisystem used for nitrosylation
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11 cm Criterion strips from Bio-Rad were rehydrated as described before and were
focused  for  the  first  dimension  with  a  multiphor  apparatus  from Amersham.  The
programme includes two steps: 1) increase of voltage up to 5000V for 5 h and 2)
maintenance of voltage at 5000V for 2 hours. The second dimension was performed
into a Biorad multi-chamber filled with Tris-Glycine buffer. The strips were loaded on
4-20%  Tris-Glycine  gels.  Then  the  gels  were  stained  with  Coomassie  blue  and
picked as described before. 
II.2.11-DEAE-ion exchange chromatography
Mouse brains were homogenized in a Potter homogenizer with 12 strokes at 800rpm.
The  homogenate  was  centrifugated  at  800xg  for  10  min  at  4°C.  The  resulting
supernantant  was further  centrifugated at  10000xg for  15min  at  4°C.  Finally,  the
supernatant was centrifugated at 50000xg for 60 min at 4°C. The cytosolic part was
either directly applied onto 10% SDS Polyacrylamide gels or further fractionated by
DEAE-ion exchange column. For the fractionation, the sample was first filtrated and
desalted in HiTrap desalting column (3 times 5 ml column), thereafter 15 mg of brain
cytosol was loaded on DEAE column and was eluted by a salt gradient up to 500mM
NaCl.
The DEAE column used for this study was a 5PW Glass column (internal diameter 8
mm and 7.5cm length) from TOSOH BIOSEP, with a TSK polymer gel.
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III-RESULTS
III.1-ROLE OF ACTIVATED MICROGLIA CELLS IN INFLAMMATOTY PROCESSES
II.1.1- 2D proteins map
Proteomic  analysis  using  2D-gel  electrophoresis  and  matrix  assisted  laser
desorption-mass spectrometry (MALDI-MS) for protein separation and identification
was  applied  to  purified  cytosolic  extracts  from  microglia  cells  that  were  either
untreated  (control)  or  were  stimulated  for  24  hours  with  a  mixture  of  cytokines
including 1 nM IL-1β and 1nM TNF-α. A total of 3 identically run 2D-gels with extracts
from control and cytokine-stimulated cells were used for the study. Only spots which
appeared  on  all  gels  were  picked  and  analysed.  Thus,  a  total  of  345  different
proteins were identified with isoelectric point values (pI) ranging from 4.5 to 10.4 and
molecular weights in the range of Mw 14.9 KDa and Mw 123.7 KDa. 
For a correct analysis of the data, a normalization of values has been performed.
Indeed, different numbers of  spots were picked on each gel. The total  number of
spots  picked  in  control  and  treated  samples  has  to  be  the  same  for  a  correct
appreciation of  a change in protein  levels. For this calculation,  the control  values
were used as a baseline and a correlation coefficient according to the total number
of spot was applied on the others values. With this system, 53 of the 354 identified
proteins were found to be upregulated with a range of ≥1.5 fold increase (Table 1).
Table  2  shows  82  proteins  that  were  found  to  be  down  regulated  (≥1.5  fold
decreased).
After the MS measurement, up- or down-regulated proteins were grouped according
to  their  functions  as  shown  in  Fig  6  and  7.  Up-regulated  proteins  have  been
classified  into  10  groups  (Fig  6)  including  proteins  involved  in  stress,  structural
constituents  of  cytoskeleton,  transport  processes,  hydrolase  activity,
oxydoreductases, transferases, or other kinase activities, proteins involved in signal
transduction as well as proteins involved in cell communication and organization.
Down-regulated proteins were classified in 16 groups (Fig 7): the same spectrum as
described  above  plus  metal  ion  binding  proteins;  proteins  with  kinase  inhibitor
activities;  proteins  involved in  metabolism;  ubiquitin  conjugating  enzyme;  proteins
involved in development and proteins with  unknown function.
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Table 1
List of up-regulated proteins
swiss prot pi Mr(kDa) fold induction protein description
sw:TKT_HUMAN 7,62 67,8 14,4 transketolase
sw:ALBU_HUMAN 6,2 71,3 5,4 serum albumin precursor
sw:TPM4_HUMAN 4,48 28,5 4,8 tropomyosin alpha 4 chain
sw:ENPL_HUMAN 4,6 92,7 4,2 endoplasmin precursor 
sw:PRO1_HUMAN 8,35 14,9 4,2 profilin i
sw:UAP1_HUMAN 6,3 58,8 4,2 udp-n-acetylhexosamine pyrophosphorylase
sw:TCPA_HUMAN 6 60,3 4,2 t-complex protein 1, alpha subunit
sw:PDI_HUMAN 4,6 57,1 3,6 protein disulfide isomerase precursor
sw:VINC_HUMAN 5,43 123,7 3,6 vinculin
sw:CH60_HUMAN 5,64 61 3,6 60 kda heat shock protein, mitochondrial precursor
sw:SERA_HUMAN 6,68 56,6 3,6 d-3-phosphoglycerate dehydrogenase
sw:SERC_HUMAN 7,65 40,4 3,6 phosphoserine aminotransferase 
sw:TBA4_HUMAN 4,8 49,9 3,03 tubulin alpha-4 chain
sw:AAC4_HUMAN 5,21 104,8 3 alpha-actinin 4
sw:AMPL_HUMAN 6,71 52,6 3 cytosol aminopeptidase
sw:MYH9_HUMAN 5,4 22,6 3 myosin heavy chain, nonmuscle type a
sw:MX1_HUMAN 5,68 75,4 2,6 interferon-regulated resistance gtp-binding protein mxa
sw:FSC1_HUMAN 7,2 54,3 2,55 fascin
sw:CYPH_HUMAN // // 2,4 peptidyl-prolyl cis-trans isomerase a
sw:G6PD_HUMAN 6,9 59,1 2,4 glucose-6-phosphate 1-dehydrogenase
sw:TPM2_HUMAN 4,47 32,8 2,4 tropomyosin beta chain 
sw:ACTS_HUMAN 5,15 42 2,4 actin, alpha skeletal muscle
sw:LDHA_HUMAN 8,34 36,5 2,34 l-lactate dehydrogenase a chain
sw:AAC1_HUMAN 5,14 103 2,25 alpha-actinin 1
sw:TBB1_HUMAN 4,6 49,7 2,22 tubulin beta-1 chain
sw:HS27_HUMAN 6,37 22,7 1,92 heat shock 27 kda protein
sw:UGDH_HUMAN 7,08 55 1,8 udp-glucose 6-dehydrogenase
sw:143E_HUMAN 4,5 29,1 1,8 14-3-3 protein epsilon
sw:CAZ2_HUMAN 5,7 32,8 1,8 f-actin capping protein
sw:COF2_HUMAN 8,1 18,7 1,8 cofilin, muscle isoform 
sw:DDH2_HUMAN 5,92 29,6 1,8 ng,ng-dimethylarginine dimethylaminohydrolase 2
sw:IEFS_HUMAN 6,8 62,6 1,8 stress-induced-phosphoprotein 1
sw:PBEF_HUMAN 7,16 55,5 1,8 pre-b cell enhancing factor precursor
sw:PUR9_HUMAN 6,7 64,6 1,8 bifunctional purine biosynthesis protein purh
sw:TCPZ_HUMAN 6,7 58,4 1,8 t-complex protein 1, zeta subunit
humangp:CHR3-Q9Y3F5 7,1 // 1,8 tr:q9y3f5: a6 related protein 
sw:143T_HUMAN 4,51 27,7 1,8 14-3-3 protein tau 
sw:IRE1_HUMAN 6,66 98,4 1,8 iron-responsive element binding protein 1 
sw:KPR1_HUMAN 6,9 34,7 1,8 ribose-phosphate pyrophosphokinase i 
sw:PSA1_HUMAN 6,6 29,5 1,8 proteasome subunit alpha type 1 
sw:SODM_HUMAN 8,4 24,8 1,8 superoxide dismutase 
sw:TCPG_HUMAN 6,6 60,4 1,8 t-complex protein 1, gamma subunit 
sw:RAN_HUMAN 7,52 24,4 1,68 gtp-binding nuclear protein ran
sw:HS71_HUMAN 5,4 70 1,61 heat shock 70 kda protein 1
sw:ALDR_HUMAN 7 35,7 1,6 aldose reductase
sw:143Z_HUMAN 4,54 27,7 1,6 14-3-3 protein zeta/delta
sw:KPY1_HUMAN 7,6 57,8 1,52 pyruvate kinase
sw:LDHB_HUMAN 5,96 36,5 1,5 l-lactate dehydrogenase b chain 
sw:CAP1_HUMAN 8,09 51,5 1,5 adenylyl cyclase-associated protein 1 
sw:CNE1_HUMAN 5,66 59 1,5 copine i
sw:GBLP_HUMAN 7,64 35 1,5 guanine nucleotide-binding protein beta subunit-like protein 12.3
sw:SPSY_HUMAN 4,71 41,2 1,5 spermine synthase
sw:TI47_HUMAN 5,21 47 1,5 cargo selection protein tip47 
Table2
List of down-regulated proteins     
swiss protein number Pi MW(KDa)
fold
induction protein identification  
sw:GR75_HUMAN  6  73.6 10 stress-70 protein, mitochondrial precursor  
sw:K1CI_HUMAN 5 61.9 9 keratin, type i cytoskeletal 9  
sw:IPYR_HUMAN 5.7 32.6 8.33 inorganic pyrophosphatase  
sw:NDKA_HUMAN 6.1 17.3 6.66 nucleoside diphosphate kinase a  
sw:GTP_HUMAN 5.37 23.2 5.55 glutathione s-transferase p  
humangp:CHR6-Q8TDM4  / / 5 tr:q8tdm4: acetyl coa transferase-like protein.  
sw:CRKL_HUMAN 6.73 33.7 5 crk-like protein.  
sw:DUT_HUMAN 10.4 26.7 5
deoxyuridine 5'-triphosphate nucleotidohydrolase,
mitochondrial precursor  
sw:PSB1_HUMAN 8.19 26.5 5 proteasome subunit beta type 1  
sw:2AAA_HUMAN 4.81 65 4 serine/threonine protein phosphatase 2a, 65 kda  
sw:CLI4_HUMAN 5.36 28.7 4 chloride intracellular channel protein 4  
sw:PRSX_HUMAN 7.5 44.2 4 26s protease regulatory subunit s10b  
sw:PSA4_HUMAN 7.73 29.5 4 proteasome subunit alpha type 4  
sw:PSB2_HUMAN 7.02 22.8 3.33 proteasome subunit beta type 2  
sw:6PGL_HUMAN 5.97 27.5 3.33 6-phosphogluconolactonase  
sw:ACTC_HUMAN 5.15 42 3.33 actin, alpha cardiac.  
sw:GDIR_HUMAN 4.85  23.2 3.33 rho gdp-dissociation inhibitor 1  
sw:IMB1_HUMAN 4.51 97.1 3.33 importin beta-1 subunit  
sw:LGUL_HUMAN 5.15 20.6 3.33 lactoylglutathione lyase.  
sw:PSD9_HUMAN  6.95  24.6 3.33 26s proteasome non-ATPase regulatory subunit 9  
sw:PTD4_HUMAN 7.89 44.7 3.33 putative gtp-binding protein  
sw:RINI_HUMAN 4.54 49.8 3.33 placental ribonuclease inhibitor  
sw:RSP4_HUMAN 4.62 32.8 3.33 40s ribosomal protein sa  
sw:TF1B_HUMAN 5.62 88.5 3.33 transcription intermediary factor 1-beta .  
sw:PUR4_HUMAN  5.81 144.6 3.3 phosphoribosylformylglycinamidine synthase  
sw:FAAA_HUMAN 6.93 46.4 3 fumarylacetoacetase  
sw:K1CR_HUMAN 5.22 47.9 3 keratin, type i cytoskeletal 18  
sw:PSE1_HUMAN 5.9 28.7 2.77 proteasome activator complex subunit 1  
sw:PDX1_HUMAN 8.18 22.1 2.5 peroxiredoxin 1  
sw:BID_HUMAN 5.19 21.9 2.5 bh3 interacting domain death agonist (bid).  
sw:PNPH_HUMAN 6.94 32.1 2.5 purine nucleoside phosphorylase  
sw:PSA2_HUMAN 7.51 25.7 2.5 proteasome subunit alpha type 2  
sw:UBL1_HUMAN 5.28 24.8 2.5 ubiquitin carboxyl-terminal hydrolase isozyme l1  
sw:PGK1_HUMAN 8.1 44.6 2.3 phosphoglycerate kinase 1  
sw:KCRB_HUMAN 5.37 42.6 2.22 creatine kinase, b chain.  
sw:PDX2_HUMAN 5.8 21.9 2.08 peroxiredoxin 2  
sw:ANX2_HUMAN 7.82 38.5 2 annexin a2  
humangp:CHR1-ENOA  /  / 2 sw:enoa_human: alpha enolase  
sw:AKA1_HUMAN 6.78 36.4 2 alcohol dehydrogenase  
sw:APT_HUMAN 5.88 19.5 2 adenine phosphoribosyltransferase  
sw:AR72_HUMAN  7.1 39.6 2 aflatoxin b1 aldehyde reductase 1  
sw:CRK_HUMAN 5.52 33.8 2 proto-oncogene c-crk (p38)  
sw:GRB2_HUMAN 6.26 25.2 2 growth factor receptor-bound protein 2  
sw:IF2A_HUMAN 4.84 36 2 eukaryotic translation initiation factor 2 subunit 1  
sw:K22E_HUMAN 8.08 65.8 2 keratin, type ii cytoskeletal 2 epidermal  
sw:METK_HUMAN 6.45 43.6 2 s-adenosylmethionine synthetase gamma form  
sw:P2AA_HUMAN 5.3  35.6 2 serine/threonine protein phosphatase 2a,  
sw:PDA6_HUMAN 6.71 27.4 2 protein disulfide isomerase a6 precursor  
sw:RBB7_HUMAN 4.77  47.8 2 histone acetyltransferase type b subunit 2  
sw:SWS1_HUMAN 4.97 26.7 2 swiprosin 1.  
sw:TBBX_HUMAN 4.65 49.6 2 tubulin beta-5 chain  
40
sw:TEBP_HUMAN 4.16 18.7 2 telomerase-binding protein p23  
sw:UNRI_HUMAN 4.85 38.4 2 unr-interacting protein  
sw:TAG2_HUMAN 8.34 22.4 1.66 transgelin 2  
sw:PDX6_HUMAN 6.31 25 1.66 peroxiredoxin 6  
sw:143B_HUMAN 4.58 27.9 1.66 14-3-3 protein beta/alpha .  
sw:TCPH_HUMAN 7.61 59.4 1.66 t-complex protein 1, eta subunit  
sw:KPR2_HUMAN 6.59 34.6 1.66 ribose-phosphate pyrophosphokinase ii  
sw:RUV1_HUMAN 6.38 50.2 1.66 ruvb-like 1  
sw:UBA1_HUMAN  5.57  117.8 1.66 ubiquitin-activating enzyme e1  
sw:GUAA_HUMAN 6.85 76.7 1.66 gmp synthase  
sw:IF32_HUMAN  5.44 36.5 1.66 eukaryotic translation initiation factor 3 subunit 2  
sw:KC21_HUMAN 7.84 45.1 1.66 casein kinase ii, alpha chain ).  
sw:KCY_HUMAN 7.84 22.2 1.66 ump-cmp kinase  
sw:PUR6_HUMAN 7.17  47 1.66 multifunctional protein ade2  
sw:TCPE_HUMAN 5.42 59.7 1.66 t-complex protein 1, epsilon subunit  
humangp:CHR19-O95717  / / 1.66
tr:o95717: sumo-1-activating enzyme e1 n
subunit.  
sw:ACY1_HUMAN  6.13  45.8 1.66 aminoacylase-1  
sw:ANX3_HUMAN 5.78  36.3 1.66 annexin a3  
sw:AR34_HUMAN  7.3 34.3 1.66 arp2/3 complex 34 kda subunit  
sw:CDK4_HUMAN 7 33.7 1.66 cell division protein kinase 4  
sw:EF1D_HUMAN 4.7 31.1 1.66 elongation factor 1-delta  
sw:HS72_HUMAN  5.51 70 1.66 heat shock-related 70 kda protein 2  
sw:PDX4_HUMAN 6.25 30.5 1.66 peroxiredoxin 4 .  
sw:PRS4_HUMAN  6.1  49.1 1.66 26s protease regulatory subunit 4 (p26s4).  
sw:PSA7_HUMAN 8.73 27.8 1.66 proteasome subunit alpha type 7  
sw:PUR2_HUMAN 6.68 107.7 1.66
trifunctional purine biosynthetic protein adenosine-
3  
sw:ROK_HUMAN  5.28  50.9 1.66 heterogeneous nuclear ribonucleoprotein k  
sw:SPEE_HUMAN 5.26 33.8 1.66 spermidine synthase  
sw:TPM1_HUMAN 4.5 32.7 1.66 tropomyosin 1 alpha chain  
sw:UBC7_HUMAN 8.75 17.8 1.66 ubiquitin-conjugating enzyme e2-18 kda ubch7  
The representation of up- and down-regulated proteins (Fig. 6 and 7) demonstrates a
different  repartition of  proteins  (The colors used in tables  for  each function have
been  maintained  for  the  representation).  For  example,  the  cytoskeleton  binding
protein group is composed of more up- than down-regulated proteins: 11 proteins
compared to only one protein, respectively.  These findings point to an important role
of cytoskeleton proteins during inflammatory processes. In contrast, proteins such as
hydrolase and transferase activities are preferentially down-regulated.
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 Fig 6:  Representation  of  the repartition of  up-regulated proteins according to their
functions. Repartition in 10 different groups
 Fig 7: Representation of the repartition of down-regulated proteins according to
their functions. Repartition in 16 groups
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Impaired cellular energy metabolism as well as increased oxidative stress are typical
features  of  many  age-related  diseases  such  as  AD.  Proteins  involved  in  kinase
inhibition,  metabolism  and  ubiquitin-conjugating  enzyme  activity  are  exclusively
found to be down-regulated. We found two differents ubiquitin-conjugating enzyme
E1 and E2-18Kda down-regulated.  Loss of  function of  ubiquitynation,  co-factor of
ATP-dependent proteolysis, has been shown to be sufficient to cause familial forms
of  neurodegenerative  diseases  by  stopping  the  clearance  of  gamma-secretase
(BACE) or playing a role in Aβ neurotoxicity. This supports the idea that metabolism
and  mostly  glycolysis  and  proteolysis  are  down-regulated  mechanisms  during
inflammation in age-related neurodegenerative diseases.
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III.1.2- Identification of up and down –regulated proteins
III.1.2-1- Up-regulated proteins
In our studies, the most up-regulated protein is Transketolase (TKT) (Table 1,
Fig. 8-A) that is 14-fold induced by the cytokine treatment. TKT has a transferase
activity and is a key protein in the pentose pathway. The involvement of TKT in AD
brain has been discussed and may be related to its anti-oxidant functions.
Several  cytoskeleton  binding  proteins  were  found  to  be  up-regulated  by
inflammatory cytokines.  This  group includes proteins  such as Profilin  and Cofilin,
which  are  up-regulated  by  4.2  and  1.8  fold,  respectively.  Impaired  cytoskeletal
functions might contribute to neuronal or synaptic damage that occurs in AD. For
example,  cofilin  was shown to initiate  or  to  enhance the progression  of  different
neurodegenerative disorders such as AD.
Interestingly,  proteins  involved  in  signal  transduction,  including  several
subunits of 14-3-3 protein: Epsilon (143E), Tau (143T) and Zeta (143Z), respectively
are increased by 1.8,  1.8  and 1.6  fold,  and have been shown to  be  involved in
neurodegenerative diseases. The subunit Zeta has clearly been identified as a tau
protein  effector  and  may  trigger  or  modulate  abnormal  phosphorylation  of  tau
protein. 
A protein classified in the chaperone group, T-complex protein-1(TCP-1) has
three different subunits found to be up-regulated: Alpha (TCP-A) by 4.2 fold, Gamma
(TCP-G)  by  1.8  and  zeta  (TCP-Z)  by  1.8  fold.  The  tubulin  beta-1  (TBB1),  up-
regulated 2.2 fold, and classified in the same chaperone group, is the more specific
substrate of TCP-1Z. A dysregulation of these proteins has been found in AD and
may be associated with the misfolding of proteins during AD. In contrast, two other
subunits  of  TCP-1  were  found  to  be  down-regulated:  Epsilon  (TCPE)  and  Eta
(TCPH),  both  by  1.6  fold.  TCP-1E has  been  shown to  be  involved in  cell  cycle
regulation and is thought to play a role in neurodegenerative disorders.
Pre-B-cell  enhancing  factor  (PBEF),  involved  in  cell  communication  and
organization, was found to be upregulated by 1.8 fold. Surprisingly, this protein which
is involved in the maturation of B-cell precursors has been shown to be highly up-
regulated in presence of cytokines such as IL-1β and TNF-α.
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III.1.2-2- Down-regulated proteins
Proteins with hydrolase activity are the most down-regulated proteins following
cytokine treatment (Table 2). In addition, one of the most down-regulated proteins is
nucleoside diphosphate kinase a (NDKA) (Table 2, Fig. 8-B) which has a transferase
activity.  This  protein  is  down-regulated  by  6.6  fold  upon  cytokine  stimulation  of
microglial cells.
Another protein known to play a role in degenerative disorders is cell division
kinase 4 (CDK4). In our study, this protein is classified in the group of protein with
transferase activity and was found to be down-regulated (1.6 fold). Cdks have been
shown to be suppressed in neurodegenerative disorders such as AD or Parkinson’s
disease.
Proteins such as Ser/Threonine phosphatase 2A (2AAA) play a role in tau
phosphorylation  and  its  impairment  has  been  shown  to  contribute  to  abnormal
hyperphosphorylation of tau. Inhibition of this phosphatase delays ERK inactivation
which  leads  to  increased  tau  phosphorylation.  In  our  in-vitro model  system,  the
cytokine-stimulated microglial cells, 2AAA was found to be markedly down-regulated
(4-fold).
Phosphorylation  of  eukaryotic  initiation  factor-2  alpha  (IF2A)  via  RNA
dependent  protein  kinase  (PKR)  has  been  shown  to  be  pro-apoptotic.  The
phosphorylation  of  this  factor  that  appears  in  AD inhibits  protein  translation  and
promotes neuronal  loss by apoptosis.  In  our study,  IF2A has been found  to  be
down-regulated by 2 fold.
Peroxiredoxins are antioxidant enzymes that have been hypothesized to play
an  important  role  in  the  pathogenesis  of  diverse  diseases  associated  with
neurodegeneration such as Pick’s disease, Down syndrome and AD. Actually, in our
study, peroxiredoxins 1, 2, 4 and 6 were found down-regulated (Table 2).
In conclusion, these in-vitro results obtained in a human microglia cell line, support
the important contribution of inflammatory responses as well as a role of activated
microglia  cells  in  CNS  degeneration  processes.  Further  studies  have  to  prove
whether the proteins found with changes in their expression level could be potential
drug targets. Moreover, the results obtained with activated microglial cells form the
brain for subsequent biochemical analyses of transgenic mouse models for AD. 
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                         1- TKT- control                                       2-TKT-inflammatory cytokine-treated
                     1- NDKA control                                   2- NDKA - inflammatory cytokine-treated
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Fig 8- B:
Fig 8: Representative 2D gels displaying up-regulated or down-regulated proteins. Fig8-
A  shows the up-regulation of the expression of transketolase (TKT) after cytokine
treatment of microglial cells (2-) as compared to control level (1-). The protein spot on
2D gel is marked by the red arrows in the enlarged pictures
Fig 8-B shows the down-regulation of the expression of nucleoside diphosphate kinase-
A (NDKA) after cytokine treatment of microglial cells (2-) as compared to controls (1-).
NDKA protein corresponding spot on the 2D gel is marked by the red arrows on the
enlarged pictures
Fig 8- A:
III.2- TRANSGENIC APP/PS2 MOUSE MODEL
These studies were performed with C57BL/6 control and APP/PS2 transgenic mice
provided by Dr. L. Ozmen, F.Hoffman-La Roche, Basel.  A total  of  26 SDS-PAGE
were analysed including 13 gels from control and 13 gels from transgenic mice. 
In summary, a total amount of 497 different proteins was detected. In general, all
proteins  identified  in  these  experiments  were  also  found  in  cytokine-stimulated
microglia.
70 proteins were found to be up-regulated (up to 1.5 fold, Table 3). Among those, six
proteins found to be up-regulated in mouse brain were also found up-regulated in
microglial  cell  (Table  3,  noted  by  Y).  These  proteins  include  heat  shock  70KDa
protein,  14-3-3  protein  tau  isoform,  endoplasmin  precursor,  protein  disulfide
isomerase precursor, gtp-binding nuclear protein ran and cytosol aminopeptidase.
Some  proteins  such  as  copine,  14-3-3  eta,  actin,  or  beta  actin  which  are  up-
regulated in brain are very similar or are members of the same family of proteins
which have been found up-regulated in activated microglia (Table 3, noted by S). 
On the other hand, three further proteins were found to be up-regulated in brains of
transgenic mice but  down-regulated in  cytokine-activated microglial  cell.  (Table 3,
noted by O): Ubiquitin- activating enzyme e1, 14-3-3 beta/alpha and unr- interacting
protein.
Other  proteins  such  as  TKT,  TCPG,  14.3.3  Zeta,  or  Fascin  which  were  found
induced after cytokine treatment of  microglia cells, were only slightly up-regulated
(TKT and fascin) or not changed in their expression as in the case of TCPG and
14.3.3 Zeta in the transgenic mouse model (data not shown).
In addition, 45 proteins were found to be down-regulated in the brain of the
transgenic  animal  model  of  AD (Table  4).  Notably,  proteins  such as  actin  alpha
cardiac, rho gdp-dissociation inhibitor, lactoylglutathione kyase, peroxiredoxin 1 and
6 and ser/thr protein phosphatase found to be down-regulated in transgenic animal
model were also found down-regulated in the microglia study. (Table 4 noted by Y).
Proteins  such  as  tropomyosin,  heterogeneous  nuclear  ribonucleoproteins  a2,
elongation  factor,  and  annexin  7  detected  as  down-regulated  in  mice  brain  are
members of  the same family of  proteins found to be down-regulated in activated
microglia cells (Table 4 noted by S).
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Finally, changes of proteins such as l-lactate dehydrogenase, superoxide dismutase,
actin  alpha  from muscle,  and  14.3.3  epsilon  found  in  the  AD mice  were  in  the
opposite direction as compared to the other study (Table 4 noted by O).
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Table 3: List of up-regulated proteins 
Swiss prot name fold induction Protein description Microglia 
SW:HS71_MOUSE 13.65 heat shock 70 kda protein 1 Y
SW:GB02_MOUSE 7.3 guanine nucleotide-binding protein g
SW:UBA1_MOUSE 6.37 ubiquitin-activating enzyme e1 1. O
SW:DPY5_MOUSE 6.37 dihydropyrimidinase related protein-5 
SW:GTP2_MOUSE 6.37 glutathione s-transferase p 2 
SW:CN37_MOUSE 5.46 2',3'-cyclic nucleotide 3'-phosphodiesterase 
SW:HXK1_MOUSE 5.46 hexokinase, type i 
SW:WDR1_MOUSE 4.55 wd-repeat protein 1
SW:VATE_MOUSE 4.55 vacuolar atp synthase subunit e
SW:OAT_MOUSE 4.55 ornithine aminotransferase,
SW:UCR2_MOUSE 3.6 ubiquinol-cytochrome c reductase complex core protein 2,
SW:IDHG_MOUSE 3.6 isocitrate dehydrogenase subunit gamma
SW:OS94_MOUSE 3.3 osmotic stress protein 94 
SW:P2AB_HUMAN 3.2 serine/threonine protein phosphatase 2a
SW:NFM_MOUSE 3.2 neurofilament triplet m protein
SW:SYS_MOUSE 3.1 seryl-trna synthetase
SW:PPIA_MOUSE 3 peptidyl-prolyl cis-trans isomerase a 
SW:SYN1_MOUSE 2.9 synapsin i.
SW:TERA_MOUSE 2.73 transitional endoplasmic reticulum atpase
SW:PAC1_MOUSE 2.73 protein kinase c and casein kinase 
SW:143B_MOUSE 2.73 14-3-3 protein beta/alpha O
SW:COF1_MOUSE 2.73 cofilin, non-muscle isoform.
SW:FUMH_MOUSE 2.73 fumarate hydratase, mitochondrial precursor
SW:VIME_MOUSE 2.73 vimentin.
SW:143T_MOUSE 2.73 14-3-3 protein tau Y
SW:HBB1_MOUSE 2.7 hemoglobin beta-1 chain 
SW:ENPL_MOUSE 2.7 endoplasmin precursor Y
SW:DHAM_MOUSE 2.7 aldehyde dehydrogenase, mitochondrial precursor
SW:ACY2_MOUSE 2.7 aspartoacylase 
SW:CNE6_MOUSE 2.7 copine vi S
SW:OTB1_MOUSE 2.42 ubiquitin thiolesterase protein otub1
SW:TRFE_MOUSE 2.28 serotransferrin precursor 
SW:HS9B_MOUSE 2.2 heat shock protein hsp 90-beta 
SW:HS9A_MOUSE 2.16 heat shock protein hsp 90-alpha 
SW:NSF_MOUSE 2.12 vesicle-fusing atpase 
SW:HS72_MOUSE 2 heat shock-related 70 kda protein 2 (
SW:MDHM_MOUSE 1.97 malate dehydrogenase, mitochondrial precurso
SW:GBB2_HUMAN 1.82 guanine nucleotide-binding protein
SW:PEBP_MOUSE 1.82 phosphatidylethanolamine-binding protein
SW:HS74_MOUSE 1.82 heat shock 70-related protein apg-2.
SW:PDX2_MOUSE 1.82 peroxiredoxin 2 
SW:DPY3_MOUSE 1.82 dihydropyrimidinase related protein-3
SW:CRYM_MOUSE 1.82 mu-crystallin homolog.
SW:PDI_MOUSE 1.82 protein disulfide isomerase precursor Y
SW:RAN_HUMAN 1.82 gtp-binding nuclear protein ran Y
SW:CGL1_MOUSE 1.82 cytosolic nonspecific dipeptidase 
SW:UNRI_MOUSE 1.82 unr-interacting protein O
SW:MYOP_MOUSE 1.82 inositol-1(or 4)-monophosphatase
SW:PYC_MOUSE 1.82 pyruvate carboxylase, mitochondrial precursor
SW:PRS7_MOUSE 1.82 26s protease regulatory subunit 7 
SW:UBP5_MOUSE 1.82 ubiquitin carboxyl-terminal hydrolase 5
SW:NDR1_MOUSE 1.82 ndrg1 protein 
SW:AHA1_MOUSE 1.82 activator of 90 kda heat shock protein
SW:LIS1_MOUSE 1.82 platelet-activating factor acetylhydrolase ib alpha subunit
SW:CAH8_MOUSE 1.82 carbonic anhydrase-related protein 
SW:143F_MOUSE 1.82 14-3-3 protein eta S
SW:CO1C_MOUSE 1.82 coronin 1c 
SW:FKB4_MOUSE 1.82 fk506-binding protein 4
MOUSEGP:MCHR11-
079188 1.82 tr:q8bfz3: actin. S
SW:APA1_MOUSE 1.82 apolipoprotein a-i precursor 
SW:ACT1_HELER 1.82 actin, cytoplasmic cyi. S
TR_ROD:Q91ZK5 1.82 beta actin (fragment) S
SW:SYG_MOUSE 1.82 glycyl-trna synthetase
SW:AMPL_MOUSE 1.82 cytosol aminopeptidase Y
SW:PSA_MOUSE 1.82 puromycin-sensitive aminopeptidase
SW:MK03_MOUSE 1.82 mitogen-activated protein kinase 3 
SW:FTDH_MOUSE 1.82 10-formyltetrahydrofolate dehydrogenase
SW:ARS1_MOUSE 1.82 arsenical pump-driving atpase
SW:VA0D_MOUSE 1.82 vacuolar atp synthase subunit d 
SW:ANX5_MOUSE 1.64 annexin a5
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Table 4: List of down-regulated proteins.
Swiss prot name fold induction Protein description Microglia
SW:ACTC_HUMAN 6.5 actin, alpha cardiac Y
SW:SEP6_MOUSE 5.5 septin 6.
SW:TPM3_MOUSE 4.5 tropomyosin alpha 3 chain S
SW:SEP5_MOUSE 4.5 septin 5 
SW:K1CI_HUMAN 3.3 keratin, type i cytoskeletal 9 
SW:ACT3_FUGRU 3.3 actin, cytoplasmic 3 
SW:GDIR_MOUSE 2.7 rho gdp-dissociation inhibitor 1 Y
SW:ROA2_MOUSE 2.7 heterogeneous nuclear ribonucleoproteins a2/b1 S
SW:NFM_PIG 2.2 neurofilament triplet m protein 
SW:LGUL_MOUSE 2.2 lactoylglutathione lyase Y
SW:ATPD_MOUSE 2.2 atp synthase d chain
SW:EF2_MOUSE 2.2 elongation factor 2 S
SW:NUDM_MOUSE 2.2 nadh-ubiquinone oxidoreductase 42 kda subunit
SW:FRIH_MOUSE 2.2 ferritin heavy chain
SW:PSA1_MOUSE 2.2 proteasome subunit alpha type 1
SW:MPK1_MOUSE 2.2 dual specificity mitogen-activated protein kinase kinase 1
SW:PDX1_MOUSE 2.2 peroxiredoxin 1 Y
SW:TLIP_MOUSE 2.2 toll-interacting protein
SW:P2AA_MOUSE 2.2 serine/threonine protein phosphatase 2a Y
SW:P2BA_MOUSE 2.2 serine/threonine protein phosphatase 2b
SW:LDHA_MOUSE 2.2 l-lactate dehydrogenase a chain O
SW:PD6I_MOUSE 2.2 programmed cell death 6 interacting protein
SW:MBP_MOUSE 2.2 myelin basic protein
SW:SODM_MOUSE 2.2 superoxide dismutase O
SW:SEP2_MOUSE 2.2 septin 2 
SW:ACTB_HUMAN 2.1 actin, cytoplasmic 1 
SW:TBA8_MOUSE 2 tubulin alpha-8 chain 
SW:SH32_MOUSE 2 sh3-containing grb2-like protein 2 
SW:CABV_MOUSE 2 calbindin
SW:DHCA_MOUSE 2 carbonyl reductase
SW:ACT1_ECHGR 2 actin 1
SW:SYW_MOUSE 2 tryptophanyl-trna synthetase
SW:GBLP_HUMAN 2 guanine nucleotide-binding protein beta subunit-like protein
SW:ANX7_MOUSE 2 annexin a7 S
SW:LAS1_MOUSE 2 lim and sh3 domain protein 1
TR_ROD:O35248 2 beta actin
SW:MDHC_MOUSE 1.8 malate dehydrogenase, cytoplasmic
SW:ACTG_EMENI 1.8 actin, gamma.
SW:ACTM_PISOC 1.75 actin, muscle.
SW:G3P_MOUSE 1.6 glyceraldehyde 3-phosphate dehydrogenase 
SW:NUHM_MOUSE 1.6 nadh-ubiquinone oxidoreductase 24 kda subunit,
SW:PDX6_MOUSE 1.6 peroxiredoxin 6 Y
SW:IMMT_MOUSE 1.6 mitochondrial inner membrane protein 
SW:ACTS_HUMAN 1.6 actin, alpha skeletal muscle O
SW:143E_HUMAN 1.55 14-3-3 protein epsilon O
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Tables 3 and 4 represent a summary of up- and down-regulated proteins, respectively,
detected in the brain of transgenic mouse model of human AD. Comparison of these
proteins with those obtained from the human microglia cell study, proteins noted with “Y”
were found in transgenic mice and microglia model; protein members of the same family
and detected in both studies were noted “S”; and expression of proteins found increased
in the microglia study and decreased in the transgenic animal model (or opposite) were
noted “O”
Former studies were performed using human postmortem brain material in order to
generate  a  human map of  proteins.  Results  obtained  with the  transgenic  mouse
model of AD clearly show a similar pattern of identified proteins with studies made
with  cytokine-stimulated  microglia  cells  and  human  postmortem  brain  material
(Langen et al,. 1999). 
A comparison of  results with AD human brain studies allows to distinguish some
proteins with significant differences in expression levels in control versus AD brains.
Increased levels of  14.3.3 gamma and epsilon were found in several brain
regions of AD and Down’s Syndrome (DS) brains. However, isoform 14.3.3 gamma
was not  detected  in  all  our  studies.  In  contrast,  14-3-3 epsilon  was found to  be
induced in all three models of AD (Table 5; Fountoulakis et al., 1999). 
Proteins including NDKA (down-regulated by 6.6 fold in the microglia study)
was found only slightly decreased in the transgenic APP/PS2 mice study (Table 5).
However,  in  human AD brains,  NDKA levels-  similar  to  the  microglia data-  were
found to be down-regulated (Kim et al., 2002). 
Proteins such as Peroxiredoxin (PDX-) composed of different subunits were
differently expressed in our models analysed. In human AD brain,  PDX-1 expression
was found unchanged whereas PDX-2 was increased and PDX-3 and PDX-4 were
found either increased or decreased in Down Syndrome and Pick’s disease. PDX-6
failed to show any changes in human AD brains (Krapfenbauer et al., 2003; Kim et
al., J Neural Transm. Suppl., 2001). In contrast, in our study on  induced-microglia
cells, PDX-1; -2 and -6 were found to be down-regulated but only PDX-1 and -6 were
also  down-regulated  in  the  transgenic  mouse  model.  Thus,  our  studies  reveal  a
different regulation of these proteins as compared to human AD brains.
NADH ubiquinone  oxidoreductase  24  KDa  and  75  KDa  have  been  found
down-regulated in human AD brain (Kim et al. Life Sci., 2001). Our results on the
transgenic mice model  show a decreased level  (1.6 fold)  of  the 24 KDa subunit.
However, the 75 KDa complex was not detected whereas another subunit 42 KDa
was down-regulated (2.2 fold; Table 5).
In  human  AD brains  levels  of  2’,  3’-cyclic  nucleotide-3’-phosphodiesterase
(CNPase) were found to be decreased only in the frontal  cortex (Vlkolinsky et al.
2001). Our results on mouse brains, however, show an up-regulation by 5.4 fold.
Studies on chaperones are of importance for AD and their expression level
has been shown to be aberrant according to the brain region analyzed (Yoo et al.,
2001). In the course of our study, we identified also different stress proteins, which
were either up-or down-regulated.
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Beta-soluble  N-ethylmaleimide-sensitive  factor  attachment  protein  (beta-
SNAP) was found significantly reduced in the temporal cortex of human AD brain
whereas gamma-SNAP was unchanged (Yoo et al.,2001). Our results performed on
a transgenic mouse model as compared to control mice show opposite effects with
no difference in beta-SNAP and slightly decreased levels of gamma-SNAP (1.4 fold).
Decreased  of  Stathmin  expression  was  observed  in  frontal  and  temporal
cortices  of  AD  brains  (Cheon  et  al.,  2001).  Stathmin  binds  to  two  tubulin
heterodimers  and  prevents  their  addition  on  to  the  end  of  microtubules  thereby
inhibiting tubulin polymerization. However, Stathmin was rarely detected in cytokine-
stimulated human microglial cells.
Proteins  such as the  voltage-dependent  anion  selective  channel  that  were
described by Yoo and co-workers as a protein with significant expression changes in
AD, have not been identified during our studies. (Yoo et al., Electrophoresis. 2001).
Likewise Aldehyde reductase (ALDH) and Carbonyl reductase (CBR) that were found
to be up-regulated in human AD brains (Balcz et al., 2001) could not be identified in
any of our models investigated.
In  summary,  a  large number  of  proteins  involved  in  neurodegenerative  diseases
identified in human brains, have also been found in cytokine-stimulated microglia or
in a transgenic mouse model of AD. Results of our studies suggest that the cellular
source of the proteins analyzed is to a large extent activated microglia.
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Proteins Microglia cell 
culture
Transgenic mouse
model
Human Post-
mortem  AD brain
14.3.3 ε Up-regulated Down-regulated Up-regulated
NDKA Down-regulated Non significant down
regulation
Down-regulated
Peroxiredoxin-1 Down-regulated Down-regulated No change
Peroxiredoxin-2 Down-regulated Not detected Up-regulated
Peroxiredoxin-6 Down-regulated Down-regulated No change
NADH ubiquinone
oxidoreductase 24KDa
Not detected Down-regulated Down-regulated
β-SNAP Not detected No change Down-regulated
Stathmin No change Not detected Down-regulated
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Table 5 : Representation of changes in protein expression in three different  experimental models:
microglia cell cultures, transgenic mouse model and human post mortem AD brain were used
III.3- ANALYSIS OF NITRATED PROTEINS AND THEIR POTENTIAL ROLE IN
ALZHEIMER’S DISEASE
III.3.1- Characterization of an antibody against nitrated tyrosine residues
III.3.1-1- Generation of the NOY-1 antibody
For this project, a specific antibody directed against tyrosine nitrated proteins was
required.  The antibody NOY-1 was generated by Dr.  Manfred Brockhaus from F.
Hoffmann-La Roche AG, Basel.   Antiserum was generated by NOY-1 immunisation
of mice using in vitro nitrated ovalbumin. The hybridoma was selected for reactivity
against nitrated BSA and lack of reactivity against non-nitrated OVA and BSA. The
main specificity was expected to be against nitro-tyrosine residues, but, like for all
hapten specific antibodies, crossreactivities cannot be ruled out. For this reason, we
performed detailed experiments to characterize the NOY-1 antibody specificity.
III.3.1-2- Specificity of the antibody
In order to prove the capacity of the antibody to recognize tyrosine-nitrated proteins,
we used nitrated human albumin. Nitration was performed in vitro by application of
Tetranitromethane (Crow et al., 1996). The albumin was first dialysed against Tris
buffer (pH 8) overnight. Then 10mM of Tetranitromethane was added to the albumin
for 30 min at room temperature. Five successive washes with the Tris- buffer were
done to eliminate excess of Tetranitromethane. Finally, the albumin can be loaded
onto a SDS-PAGE .
Different amounts of nitrated human albumin (40µg and 20µg, lines 1,2 in Fig 11)
and non-nitrated human albumin (40µg and 20µg, lines 3,4 in Fig 11) were loaded on
4-20% SDS-PAGE and used for Western-blot analysis. 
The results presented in Fig. 9 clearly show that the antibody specifically recognizes
nitrated proteins (lanes 1 and 2).
    1     2     3     4    5
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Fig 9: Western blot analysis of nitrated human albumin using the
antibody NOY-1.
 1- 40µg of in vitro nitrated human albumin
 2- 20µg of in vitro nitrated human albumin
 3- 40µg of human albumin
 4- 20µg of human albumin
 5- 40µg of in vitro nitrated human albumin quenched.
Lanes 1 and 2 show the detection of nitrated human albumin
(Mol. Wt. 66 Kda)
To check the ability of the antibody to recognize exclusively nitrated proteins and to
eliminate  albumin  crossreactivity,  three  other  purified  proteins  with  different
molecular weights were selected:  DnaK (heat  shock protein 69 KDa);  GrpE (10.4
KDa) and MurD (46 KDa) and 100ng of each were separated on SDS-PAGE (Fig
10).
Western blot analysis revealed that the antibody recognized specifically the nitrated
proteins (lines 2, 4, 6 and 8), but not the non-nitrated proteins (lines 1, 3, 5, and 7). 
          
For comparison of the obtained results, a commercially available antibody (JURO)
against  tyrosine  nitrated  proteins  was  used  for  parallel  experiments.  In  these
experiments,  the identical  amounts of  nitrated proteins were used for  SDS-PAGE
and Western-blot analysis. However, this antibody, as compared to NOY-1 antibody,
detected the nitrated proteins with a much lesser signal intensity (data not shown). 
III.3.1-3- Quantification of the detection limit of the NOY-1 antibody
In a next step of characterization of our antibody, experiments were performed to
determine the minimal  amount  of  nitrated proteins that  can be detected  with  the
antibody. Different amounts of nitrated human albumin ranging from 1 pg to 100 ng
were applied to SDS-PAGE and Western blot  analyses using NOY-1. Our results
show that a protein amount as low as 100 ng e.g nitrated albumin is sufficient for a
correct reproducible detection by NOY-1 (Fig. 11).
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Fig 10: Western-blot analysis with NOY-1 antibody
of proteins with different molecular weights:
1-100ng  of  human  albumin;  2-100ng  of  human
albumin  nitrated;  3-100ng  of  DnaK;  4-100ng  of
DnaK nitrated;  5-100ng of GrpE;  6-100ng of GrpE
nitrated; 7-100ng of MurD; 8-100ng of MurD nitrated
       1      2      3     4     5     6
  
III.3.2- Analysis of nitrated proteins with MALDI-MS
For further analysis by MALDI, theoretical molecular data are required. Nitration on
tyrosine leads to addition of a NO2 group linked by an Hydrogen (H) on the protein.
This additional group triggers a shift  of 45 Da in the total molecular weight of the
protein fragment. This change into the mass has been observed and quantified by
MS (Fig.12).
III.3.3- Identification of nitrated peptides with Poseidon software
Supernatants  from  the  cortex  of  control  and  APP/PS2  mice  were  obtained  by
centrifugation steps as described in Material and Methods. These supernatants were
focussed with the minisystem from Invitrogen as described in Material and Methods.
The second dimension was done with 10% Bio-Rad gels. 
Two gels were transferred onto nitrocellulose membranes and were immunostained
with NOY-1 antibody whereas two other gels were stained with Coomassie blue. On
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Fig 12: Mass spectrum showing the 45 Da shift obtained during a measurement of a
nitrated protein by MALDI- TOF apparatus
Fig  11:   Determination  of  the  detection  limit  of  NOY-1
antibody:
 1- 100ng of nitrated human albumin;  2-10ng of nitrated
human albumin;  3- 1ng of nitrated human albumin;
 4- 100pg of nitrated human albumin;   5- 10pg of nitrated
human albumin;  6- 1pg of nitrated human albumin.
Lane 1 show that  100ng of  nitrated human albumin (66
KDa)  is  an  minimum  amount  clearly  detectable  by  the
NOY-1 antibody
MW
(Kda)
98
64
these Commassie gels, the protein spots that correspond to antibody stained spots
were  picked  as  described  in  Material  and  Methods.  Only  nitrated  proteins  were
picked with this method (data not shown).
MS measurement of these samples are of help to obtain a map of proteins. Then, a
software  (Poseidon,  F.  Hoffmann-La  Roche  AG)  was  used  which  permitted  to
analyse all peptides containing tyrosine residues and to select proteins which display
different nitration patterns in AD than in control cortex, including:  triosephosphate
isomerase  (TPIS);  Beta  actin  (ACTB),  tubulin  beta  5  chain  (TBB5),
dihydropyrimidinase related protein 2 (DPY2);  rab gdp dissociation inhibitor alpha
(GDIA); tubulin alpha 1 chain (TBA1) and aldolase C (ALFC).
Table 6 demonstrates that the expression level of  these proteins in AD cortex as
compared to controls was different. For example, in AD brains ACTB is clearly down-
regulated by 1.8 fold  whereas TBA1 is highly up-regulated (5 fold).  On the other
hand, ALFC expression is only slightly increased in AD samples (1.2 fold).
control AD
TPIS 33 30
ACTB 135 75
TBB5 68 42
DPY2 126 114
GDIA 10 15
TBA1 2 10
ALFC 38 48
Nitration  of  these  proteins  was  tested  with  the  help  of  internal  software  from
F.Hoffmann-La Roche. For example, this theoretical measurement revealed aldolase
C (ALFC) as the protein  with  the  most  pronounced changes in  peptide nitration.
Aldolase C, a molecule of 39 kDa, is a key enzyme of the glycolytic pathway and is
specifically expressed in brain.
The  other  proteins  listed  in  Table  6  are  not  further  analyzed  yet  but  could  be
potential  candidates  as marker  molecules  for  inflammatory  degeneration.  Indeed,
TBB5, TBA1 and ACTB are cytoskeleton binding proteins, and their functions are
impaired in AD. DPY2, a protein of interest in axonal guidance, has been already
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Table 6: Number of identification of each protein in 2D gels of cortex of
control and in AD transgenic mouse. The analysis was performed with
MALDI-TOF
described  to  be  involved  in  neurodegenerative  events  such  as  AD.  GDIA  is  a
molecule participating in intracellular trafficking and a loss of function of this protein
can finally leads to alteration of vesicle exocytosis.
III.3.3-1- Identification of Y-nitrated peptides in ALFC sequence
Five different  nitrated  peptides  from ALFC protein  have been  identified  by  mass
spectrometry (Fig 13).
   1- YSPEEIAMATVTALRR
   2- CIGGVIFFHETLYQK
   3- AEMNGLAAQGRYEGSGDGGAAAQSLYIANHAY
   4- PHSYPALSAEQKK
   5- CPLPRPWALFFSYGR.
These five peptides represent different parts of the ALFC- protein (Fig 14).
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       1   PHSYPALSAE QKKELSDIAL RIVTPGKGIL AADESVGSMA KRLSQIGVEN 
      51  TEENRRLYRQ VLFSADDRVK KCIGGVIFFH ETLYQKDDNG VPFVRTIQDK 
    101  GILVGIKVDK GVVPLAGTDG ETTTQGLDGL LERCAQYKKD GADFAKWRCV 
    151  LKISDRTPSA LAILENANVL ARYASICQQN GIVPIVEPEI LPDGDHDLKR 
    201  CQYVTEKVLA AVYKALSDHH VYLEGTLLKP NMVTPGHACP IKYSPEEIAM 
    251  ATVTALRRTV PPAVPGVTFL SGGQSEEEAS LNLNAINRCP LPRPWALTFS 
   
    301  YGRALQASAL NAWRGQRDNA GAATEEFIKR AEMNGLAAQG RYEGSGDGGA 
    351  AAQSLYIANH AY
Fig 13: List of peptides derived from aldolase C (ALFC) that
were nitrated acording to MS analysis.
Fig 14: Representation of the amino acid composition of ALFC protein. Peptides of interest
are represented in color
Total number of nitrated peptides amounted to 29 in control and to 42 in APP/PS2
mice.  These  results  demonstrate  that  there  are  more  nitrated  ALFC-peptides  in
APP/PS2 mice than in controls and that this level is increased by about 1.4 fold. The
most  important  peptide  is  AEMNGLAAQG  RYEGSGDGGAAAQSLYIANH  AY,
because nitration of the tyrosine amino acid (Y) at the carbon terminal is a key event
that leads to a loss of function of the protein (Fig 14). 
Since the data are based on theoretical analysis, results have to be confirmed by
experimental studies. Our goal is to visualize this increase in nitration of the ALFC-
protein  by  immunocytochemistry.  Immunohistochemical  studies  with  a  specific
antibody that could detect the ALFC protein is needed.
control AD
YSPEEIAMATVTALRR 21 25
CIGGVIFFHETLYQK 6 11
AEMNGLAAQGRYEGSGDGGAAAQSLYIANHA
Y
1 -
 PHSYPALSAEQKK - 1
CPLPRPWALFFSYGR. 1 5
                       TOTAL of the nitrated peptides 29 42
III.3.3-2- Detection of  ALFC protein by  antibodies 
For  this  project,  the  cytosolic  part  of  homogenates  from  control  mice  brain  was
loaded onto 4-12% NuPAGE gels. The proteins were transferred to  nitrocellulose
membranes for Western blot analysis using ALFC antibody. First, two commercially
available antibodies from Santa Cruz Biotechnology were used. One was directed
against the N-terminal part (N14) and the second  antibody was directed against an
internal part (D14) of the protein.  The more specific antibody was D14 that detected
the protein ALFC at 39 KDa with less background than N14 (data not shown). The
detection of ALFC by D14 is shown in Fig 15 by the green arrow.  
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Table 7: Number of peptides of ALFC displaying Y-nitration found in control or APP/PS2 transgenic
mice
III.3.3-3- Co-Immunoprecipitation
An important goal of our study was to verify a change in the nitration of ALFC in AD
brain. For this purpose, we have performed co-immunoprecipitations of control and
AD samples with either the ALFC antibody D14 , NOY-1 antibody  or Cytochrome-C
antibody.  The  samples  were loaded  in  4-12 % NuPAGE gels,  and  Western  blot
analysis was performed, using the three antibodies. The results are represented in
Fig 16.
On Figs 16-A and -C, lanes 1 and 2  were loaded with  immunoprecipitates  from
control  samples,  and  lanes  3  and  4  from  the  cytosololic  fractions  of  APP/PS2
transgenic mice brain. On lanes 1 and 3, the immunoprecipitations were performed
with the ALFC antibody and on lanes 2 and 4 with the NOY-1 antibody. The Western
blot  analysis  was  performed  by  using  ALFC  antibody  in  Fig  16-A  and  NOY-1
antibody in Fig16-C.
Our results show a positive signal about 39 KDa as indicated by the green arrow (Fig
16-A  and  -C)  which  corresponds  to  ALFC  protein.  This  indicates,  that  a  co-
immunoprecipitation  of  ALFC protein with ALFC antibody and NOY-1 antibody is
effective. There was no difference in the level of ALFC expression (Fig 16-A, line 1
and 3) and no difference in the level of protein nitration (Fig 16-C, line 2 and 4).
Fig 16-B, -D and -E represent gels loaded on lane 1 with control samples and on
lane 2 with an AD sample, immunoprecipitated with Cytochrome C antibody for a
control.  Western  blot  analyses  were  performed  using  ALFC  ,  NOY-1  and
Cytochrome  C antibodies,  respectively.  The  black-arrows  (Fig  16-B,  -D  and  –E)
indicate the bands representing the Cytochrome C signal. Only very weak staining of
ALFC bound  to  cytochrome C antibody  (Green-arrow)  was found with  the ALFC
antibody (Fig. 16-B) and with NOY-1antibody (Fig 16-E).
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Fig 15: Western-blot analysis of cytosolic extracts from control
mice brain with the D14 antibody. The arrow show the detection
of aldolase C by the antibody (Mol. Wt. 39 KDa)
 In  conclusion,  even  with  the  help  of  co-immunoprecipitation,  no  significant
differences  in  ALFC  expression  levels  were  detected  between  control  and  AD
samples. Moreover, no difference in the level of nitration was detected. 
Currently, similar experiments are performed on proteins exhibiting a change in Y-
nitration  and  a  more  pronounced  change  in  expression  between  control  and
APP/PS2 mice samples. One of the proteins currently under investigation is TBA1
which is highly induced (about 5 fold) in AD brains compared to controls as shown in
Table 6. 
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Fig 16: Coimmunoprecipitation from control and APP/PS2 mice with ALFC, NOY-1 and Cytochrome C
antibodies
Fig 16-A represents a coimmunoprecipitation of control (lanes 1 and 2) and AD samples (lanes 3 and
4) with ALFC (lanes 1 and 3) and NOY-1 antibodies (lanes 2 and 4). Western blotting was performed
with ALFC antibody
Fig 16-B represents a coimmunoprecipitation of control  (lane 1) and AD (lane 2) samples with
Cytochrome C antibody and analysis by Western blotting with ALFC antibody
Fig 16-C represents a coimmunoprecipitation of control (lanes 1 and 2)and AD (lanes 3 and 4)
samples with ALFC (lanes 1 and 3) and NOY-1 antibodies (lanes 2 and 4). The western blotting was
performed with NOY-1 antibody
Fig 16-D represents a coimmunoprecipitation of control  (lane 1) and AD (lane 2) samples with
Cytochrome C antibody and analysis by Western blotting with Cytochrome C antibody
Fig 16-E represents a coimmunoprecipitation of control  (lane 1) and AD (lane 2) samples with
Cytochrome C antibody and analysis by Western blotting with NOY-1 antibody
The green arrows on each Fig represent the detection of the aldolase C (39 Kda), the blacks arrows on
Fig16-B,-D and –E represent the Cytochrom C signal
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16-A
16-C
16-B
16-D
16-E
1- Immunoprecipitation of control sample with ALFC antibody
2- Immunoprecipitation of control sample with NOY antibody
3- Immunoprecipitation of AD sample with ALFC antibody 
4- Immunoprecipitation of AD sample with NOY antibody
The western blotting was performed with an antibody against
NOY
98KDa
68KDa
49KDa
17KDa
28KDa
38KDa
1      2      3     4
1- Immunoprecipitation of control sample with 
CytochromeC antibody
2- Immunoprecipitation of AD sample with 
Cytochrome C antibody
The western blotting was performed with a antibody
against CytochromeC
98KDa
68KDa
49KDa
17KDa
28KDa
38KDa
1      2
98KDa
68KDa
49KDa
17KDa
28KDa
38KDa
1      2      3     4
1- Immunoprecipitation of control sample with ALFC antibody 
2- Immunoprecipitation of control sample with NOY antibody 
3- Immunoprecipitation of AD sample with ALFC antibody 
4- Immunoprecipitation of AD sample with NOY antibody 
The Western blotting was performed with an antibody against
ALFC
98KDa
68KDa
49KDa
17KDa
28KDa
38KDa
1     2
1- Immunoprecipitation of control sample with 
CytochromeC antibody
2- Immunoprecipitation of AD sample with CytochromeC 
antibody 
The western blotting was performed with an antibody
against ALFC
1- Immunoprecipitation of control sample with Cytochrom C antibody
2- Immunoprecipitation of AD sample with Cytochrom C antibody
Western blotting was performed with an antibody against NOY
98KDa
68KDa
49KDa
17KDa
28KDa
38KDa
1    2
In  order to  proceed with  this  study,  HPLC fractionation was performed to isolate
ALFC from the cytosolic part of mice brain. This HPLC analysis was performed with
a size exclusion column superose as described in Material and Methods. Eluated
proteins were then collected according to their molecular weight into fractions. The
flowthrough of proteins is represented by an elution profile (Fig 17). The bigger pic in
the elution profile represents the fractions in which most of  the proteins from the
initial  solution  were  eluated.  These  fractions  were  analyzed  using  an  anti-ALFC
antibody (Fig 18).
    
  
Fractions 21 to 27 were loaded on 4-12% NuPAGE gels and were analysed by
Western-blotting.
                 
ALFC could be detected in fractions 23 to 26 as shown by the green arrow in Fig 18.
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Fig 18: Western-blot analysis of the
different fractions of interest
obtained by HPLC
Fig 17: HPLC analysis of cytosolic
extracts  of  brain  from  AD  mice.
This  elution  profile  represents  the
flowthrough  of  the  proteins
according  to  their  size.  “y”  axis
represent  mS/cm  (conductivity  of
the column) and “x” axis  represent
the time expressed in minutes
MW (KDa)    27    26   25   24   23   22   21
98
62
49
38
17
28
14
A confirmation whether higher levels of ALFC nitration are indeed found in affected
AD  samples  is  still  in  progress.  For  this  purpose  LC-MS/MS,  performed  in
collaboration with Dr. Bernd Müller (F.Hoffmann-La Roche, Basel), will be used. 
LC-MS/MS is a combination of liquid chromatography and electrospray tandem mass
spectrometry  that  allows  to  eliminate  the  two-dimensional  electrophoresis.  After
protein digestion of the fraction by trypsin, the resultant peptides are directly eluted
from a Reverse Phase HPLC (RP HPLC) column into mass spectrometer.
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III.4- PROTEOMIC ANALYSIS OF SOLUBLE PROTEINS OF MICE BRAIN
These studies were performed using a control mouse model C57BL/6J (F-Hoffmann-
La Roche,  Basel)  The major  goal  was to  compare brains from control  mice with
transgenic  animal  models  of  AD and  to provide evidence of  synaptic  membrane
instability in the pathology of AD. First the technologies for the detection of synaptic
proteins had to be improved and then in a following step,  the MS sensitivity was
improved by miniaturization of the entire system.
III.4.1- Detailed protein map of cytosolic brain
The first aim of this project was to generate a detailed map of proteins of mouse
brain  cytosol.  For  this  purpose,  fractions  of  samples  obtained  by  sequential
centrifugation were submitted to DEAE-ion exchange chromatography in order  to
increase  the  amount  of  proteins  which  have  been  separated  by  2D-gel
electrophoresis . The chromatographic fractionation method employed increases the
probability  to  detect  low abundant  proteins  by reducing the  complexity of  protein
solution loaded. The ion-exchange chromatography used was adapted according to
the specific requirements of the experiment (Krapfenbauer et al., 2001). 
Brains of C57Bl/6J mice were homogenized as described in “Material and Methods”,
the  cytosolic  fractions  obtained  by  differential  centrifugation  were  worked  up
differently: 
The cytosolic part  of  the mouse brain was prepared and subjected to 10% SDS-
PAGE using the established proteomic technology. A Coomassie blue stained gel
corresponding to these samples is shown in Fig 19A.  With this method, about 625
different proteins could be identified and the repartition of the identified proteins in 16
different functional groups is shown in Fig 19B.
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On the other hand, half of cytosolic brain samples were first fractionated by DEAE-
ion exchange chromatography, performed by Remy Roland (F.Hoffmann-La Roche,
Basel)  as  described  in  “Material  and  Methods”.  Proteins  were  eluated  from  the
column according to their conductivity.  The entire spectrum obtained, representing a
different pattern of proteins, was separated into several equal parts. Fifteen fractions
displaying completely different expression patterns were selected and used for 2D
gels as shown in Fig 20.
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Fig 19A: Coomassie blue stained gel obtained from cytosolic extract derived from mouse brain
Fig 19B: Distribution of proteins according to their function. The grouping was performed
following MS measurement
Fig 20: Representative gels obtained from 15 fractions collected by  DEAE-
Chromatography
The  combined  use  of  chromatography  and  proteomic  technology  allowed  the
excision of 12’600 spots in total. 9’425 spots were identified by MALDI-TOF. From
these,  1’240  were  identified  as  different  proteins.  This  is  double  the  amount  of
protein which could be identified by the established proteomic procedure.
Identified proteins were classified in 16 groups according to their function as shown
in Fig 21. All the percentages indicated in Fig 19B and Fig 21 are according to the
total  number  of  identified  protein in  each case.  However,  we do not  exclude the
possibility that one protein could be classified in several different groups. 
The  combination  of  DEAE  chromatography  and  MS  analysis  allowed  the
identification of various proteins involved in signal transduction such as MAP kinase
kinase kinase (MEKK); extracellular signal related kinase (ERK1 and 2) , MAP kinase
kinase (MAKK1, MAKK6), ras-related protein rab (RAB), gtp binding nuclear protein
ran (RAN), RAS and rho-protein; Protein kinases such as c-AMP-dependent protein
kinase (KAP1 and 2), Ser/Threonine kinase (AKT2), IKKB, Ser/Threonine kinase pak
(PAK 1 and 3), src, CRK6; G protein-coupled receptor such as NMDA-receptor or
GABA-A receptor subunit  IV; molecules involved in synaptic transmission such as
neuronal tropomodulin (TMO2) ; molecules involved in neurotransmitter metabolism
and secretion such as catechol-O-methyltransferase (COMT) and synapsin1 (SYN1).
Using mass-spectrometry, it is the first time that downstream kinases such as ERK 1
and 2, which phosphorylate a variety of downstream proteins including other kinases
as well as gene regulatory proteins in the nucleus, could be identified. This increased
level  of  detection  could  not  be  reached  without  the  previous  chromatography
purification step.
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Fig 21: Protein classes
detected after Chromatography
This part of our study revealed a drastic improvement of the proteomic technology.
We  could  clearly  achieve  a  significant  increase  in  the  sensitivity  of  MALDI-MS
analysis by the pre-fractionation procedure of the samples using DEAE-ion exchange
chromatography.
This  improvement  is  a  major  progress  in  the  investigation  of  very  low abundant
proteins.  However,  it  should  be  mentioned  that  the  chromatographic  approaches
may have certain limits: (i) an overlap of the protein spots can occur; (ii) since high-
and low-abundant proteins are enriched, expression of high aboundant proteins can
mask the detection of low expression proteins in a 2D gel; (iii) proteins eluted from
columns usually require removal of salts used for their elution. This disalting process
can affect the composition of the mixture.
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III.5- ISOLATION OF SYNAPTOSOMES
Loss of synapses has been correlated with the degree of dementia (Callahan  2002).
Thus, it is important to investigate the changes in specific protein expression patterns
in synaptic terminals in the central nervous system of AD patients as compared to
healthy controls. 
Thus, we focused on the development of protocols for the isolation of synaptosomal
membranes from mouse brains. The experiments were initially performed on control
C57/B1/6  mice  brain  (provided by Dr.  Laurence Ozmen,  Basel).  Whole  brains of
mice  were  homogenized  and  fractionated  according  to  the  method  described  in
Material and Methods (summurized in Fig 22).
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Brain 
Homogenate
Supernatant 1Pellet 1
Pellet 2Supernatant 2
wash
Pellet 2’
Percoll
gradient
Crude synaptosomes
Supernatant Pellet
lysis
Supernatant 3 Pellet 3 (synaptic membranes)
Centrifugation step
Supernatant 4 Pellet 4 (synaptic vesicles membranes)
LoadingFig 22: Representative protocol for the isolation of brain synaptic membranes
The  purification  steps  of  synaptosomes  were  monitored  using  Western-blots
immunostained with an antibody against synaptophysin, a vesicle-membrane protein
as shown in Fig 23.
The synaptic membranes, characterized by the positive signal of the synaptophysin
antibody, are present in all fractions (lanes 1 to 10). After a first crude separation of
the synaptosomes by the Percoll gradient, two additionnal centrifugation steps were
performed to separate the membranes. These membranes are significantly enriched
in the two last pellets P3 and P4, representing the synapses and synaptic vesicles
and were not present in the cytosolic fractions S3 and S4 (lanes 14 and 16).
 
The isolation of synaptic membranes has been shown to be efficient. In a next step,
MS  analysis  was  performed  in  order  to  generate  a  map  of  proteins  present  in
synaptic  membrane  fractions.  Generally,  the  quantity  of  proteins  isolated  by  this
protocol was not sufficient to perform a normal 2D gel. Indeed, purified synaptosomal
membranes  represented  low-protein  samples  and  only  70  µg  of  proteins  was
obtained after preparation and fractionation of two total mouse brains. Therefore we
established the mini-system technology from Invitrogen which is a miniaturization of
all proteomic techniques and is of particular value for low-protein samples.  
The improvement of this technology involved desalting of samples, use of 7 cm IPG-
strips,  isoelectric  focusing  in  3  hours  and a  second  dimension  on  NuPAGE-gels
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Fig 23: Western-blot analysis of the different fractions obtained. The antibody used is anti-
synaptophysin. 1- Homogenate; 2- Supernatant 1 (S1); 3- Pellet 1 (P1); 4- S2; 5- P2;
 6- P2 washed; 7- P2’; 8- upper part of the Percoll gradient; 9- second part of the Percoll
gradient; 10- crude synaptosomes; 11 and 12- phase below; 13- bottom pellet of the Percoll
gradient; 14- S3; 15- P3; 16- S4; 17- P4. (Molecular weight  is expressed in KDa)
MW   1     2      3     4     5      6     7     8      9
98
62
49
38
28
17
MW   10  11   12   13   14    15   16    17 
(8.5mm, 9mm, 1mm). These 2D gels after staining with Coomassie-blue were further
picked and analysed by the usual apparatus used (data not shown).
This  mini-system technology is  now optimized  to  be  used for  MS measurement.
Studies  in  our  laboratory  are  in  progress  to  proceed  with  this  map  of  synaptic
membranes proteins of control and transgenic mice. Isolation of synaptosomes from
brains of  AD mice bas been performed and the samples are available  for further
studies. 
71
V-DISCUSSION
IV.1- Characterization of cytokine treated microglia cells
IV.1.1- Up- regulated proteins
IV.1.1-1-Role of transketolase
In order to search for possible biomarker molecules that could be of value for an
early diagnosis of AD, we investigated changes in proteins expression patterns that
were induced upon cytokine treatment of microglia cells.
The major finding was the upregulation of identified proteins known to be involved in
AD  or  other  neurodegenerative  disorders.  Following  stimulation  of  microglia  cell
cultures with IL-1β and TNF-α, the most upregulated protein found (up to 14 fold) is
Transketolase  (TKT),  a  thiamine  diphosphate  dependent  enzyme (Schenk  et  al.,
1998).  TKT  was  originally  isolated  from  different  sources  such  as  mouse  brain,
human leukocytes or erythrocytes. This ubiquitous enzyme catalyses two steps of
the non oxidative pentose pathway. Its biological role is to transfer the glucoaldehyde
group from xylulose-5-phosphate to ribose-5-phosphate, or erythrose-4-phosphate to
form  sedoheptulose-7-phosphate  and  fructose-6-phosphate,  respectively
(Calingasan  et  al.,1995).  In  addition,  the  TKT  gene  has  been  shown  to  be  a
metallothionein  (MT)  regulator-gene  in  MT-null  mice.  MT  proteins,  regulated  by
glucocortocoids, are known to modulate DNA binding of transcriptional factors and
are induced  under  various  conditions  such  as  cytokine-induced  stress,  and  are
thought to be involved in the tissue protection against generation of  free radicals.
Thus, in the MT-null mice, TKT was found to be up-regulated as a compensation of
MT proteins lack for oxidative stress protection  (Kimura et al., 2000).
The  involvement  of  TKT  in  AD  has  been  investigated  mainly  because
neurodegenerative  diseases  are  often  associated  with  proteolysis  that  amplifies
tissue damage (Paoletti et al., 1997 and 1998).
TKT has an heterogenous expression throughout the brain and its activity has been
shown  to  be  decreased  in  postmortem  brains  of  AD  patients (Calingasan  et
al.,1995). This decrease in enzyme activity is probably caused by reduced thiamine
concentration. Indeed, the levels of thiamine were decreased in plasma but not in
CSF of AD patients (Schenk et al., 1998; Molina et al., 2002).
Most  of  the  earlier  studies  were  done  on  postmortem  brain  materials  or  with
fibroblast cultures. In contrast, our study was performed with pure human microglia
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cell cultures. Thus, it can be hypothesized that TKT levels are increased at sites of
cytokine-activated microglia, probably in order to reduce oxidation.
IV.1.1-2- Role of cytoskeletal proteins
Proteins  involved  in  the  cytoskeleton  structure  are  of  particular  interest  in  AD
because  of  the  typical  synaptic  changes  that  occur  in  this  disorder.  The  most
important  protein  of  the  cytoskeleton  is  actin  that  has  the  ability  to  bind  several
proteins. The dynamics of this assembly is involved in a variety of cellular functions
including cell motility, vesicle transport and membrane turnover.
Actin  assembly  is  regulated  by  the  complex  actin  depolymerizing  factor  (ADF)
conjugated with cofilin which has been discovered in embryonic chicken brain (Dos
Remedios  et  al.,  2002).  This  complex  ADF/cofilin  regulates  actin  dynamics.  In
response to stress or injury, ADF/cofilin binds to actin and forms inclusions in the
nucleus.  By  immunocytochemistry,  transient  and  persistent  inclusions  containing
ADF-cofilin have been co-localized with amyloid plaques in hippocampus and frontal
cortex of human AD brains (Minamide et al., 2000 ; Bamburg et al., 2002). These rod
like inclusions  within  neurites  could  be involved in  synaptic  loss  by  inhibiting the
intracellular transport processes.
In  our  study,  cofilin  was  found  to  be  up-regulated  and  supports  the  idea  that
cytoskeleton changes could also occur in microglia cells. The loss of synapses can
be  due  to  changes  in  cytoskeleton  and  of  neuron  loss  and  subsequent  loss  of
communication with surrounding cells.
Profilin 1, a further actin binding protein, is a regulator of the microfilament system
and is involved in diverse signaling pathways (Wittenmayer et al., 2004). This low
molecular weight protein is involved in actin polymerization at the cell surface and is
necessary for synaptic morphology (Dos Remedios et al., 2002; Ackermann et al.,
2003). Studies on dendritic  spines have shown that enrichment of  profilin  and its
targeting into the cytoplasm is activity-dependent (Ackermann et al.  2003). A high
production of profilin has been shown to stabilize spine morphology. Profilin was first
studied in order to understand how the activation of postsynaptic NMDA-receptors is
transduced  to  long-term  morphological  changes.  It  is  known  that  long-term
potentiation (LTP) and long term depression (LTD) may induce profilin targeting as
well  as  actin  stabilization.  In  our  study,  profilin  was  found  up-regulated  4.2  fold
supporting the idea that profilin is overexpressed to stabilize cell morphology after
injury until the consolidation of the cell is complete (Ackermann et al., 2003).
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IV.1.1-3- Proteins Involved   in signal transduction  
 Another protein of interest is the 14-3-3 protein which consists of 7 isoforms: β,γ, ε,
η, σ, τ , and ξ. Two other isoforms (α and δ) represent phosphorylated forms of beta
β and zeta ξ (Green.,  2002).  This low molecular weight dimeric protein has been
localized  to  several  brain  regions  and  diverse  cell  types.  For  example:  the  zeta
subunit  is  more  present  in  cortical  neurons  and  in  cerebellar  Purkinje  cells.  In
contrast, the epsilon subunit is predominantly expressed in astrocytes (Richard et al.,
2003).
14-3-3 proteins are known to play a role in the regulation of signal transduction, cell
cycle pathways, apoptosis and may play a role as molecular chaperones (Richard et
al 2003; Dev et al., 2003; Fig 24).
Increased levels of 14-3-3 proteins have been described in Creutzfeld Jakob Disease
(CJD; Zerr et al., 2002; Huang et al., 2003) and at present 14-3-3 proteins are useful
marker  molecules  that  diagnostically  distinguish  between  CJD  and  other
neurodegenerative  diseases,  especially  AD  (Riemenschneider  et  al.,  2003).
However, increased levels of 14-3-3 in CSF of CJD patients are believed to be due
to an acute neuronal damage and thus are most likely not specific for this disorder
but the level of 14-3-3 in CSF is less detectable in AD brain (Green et al.,2002).
In our study, the isoforms epsilon ε, tau τ and zeta ξ were found 1.8, 1.8, and 1.6 fold
induced,  respectively.  Up  to  date,  presence  of  14-3-3  ξ  in  AD  amyloid  plaque
formation has not been confirmed, but it has been hypothesized that 14-3-3 ξ is an
effector of tau protein phosphorylation and is involved in the accumulation of tau in
AD (Hashigushi et al., 2000). No former results contradict the presence of 14-3-3 ξ in
microglia  cells  and,  perhaps,  our  data  could  confirm  the  idea  of  its  chaperone
function developed after a cytokine stress. 
On the other hand, the Epsilon subunit is claimed to be with the γ-subunit specific for
CJD. Epsilon and zeta subunits have a significantly different sequence, but 
14-3-3 ε has been also found to be increased in CSF of CJD patients. The elevated
levels of this isoform are clearly due to astrocyte activation. Our results suggest a
mimetic effect due to microglia activation.
Two other isoforms, 14-3-3-β and 14-3-3-α, were found down-regulated (1.6 fold) in
our study. However, these isoforms have not been yet described to have a particular
impact in AD.
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IV.1.1-4-   Role of chaperones  
The T-complex protein-1 (TCP-1) is classified in the chaperone group. This protein of
60  KDa represents  an  assembly  of  several  polypeptides  and  is  abundant  in  the
cytosol of all eukaryotic cell.  (Wagner et al., 2004).  Studies in human erythrocytes
have shown that a translocation of TCP-1 from the cytosol to the cytoskeleton occurs
upon  heat-stress.  Moreover,  TCP-1  is  involved  in  microtubule  growth,  tubulin
assembly and in actin polymerization. Tubulin and actin were described as the major
substrates and the more specific substrate is Tubulin β-1 (TBB1; Grantham et al.,
2002).
Our studies demonstrate that three subunits of TCP-1 are up-regulated in cytokine-
stimulated  microglia  cells:  TCP-1  Zeta  (ξ),  alpha  (α)  and  gamma (γ).  This  is  in
contradiction  with  former  studies  from  Schuller  and  co-workers  (Schuller  et  al.,
2001). The authors found the TCP-1 Zeta expression (TCP-1Z) is decreased in AD
as  well  as  the  ratio  of  TCP/TBB1.  These  controversial  results  could  be  best
explained  by  the  different  tissues  analyzed  in  the  various  studies:  the  Schuller
studies were done in six different brain regions (temporal, frontal, occipital, parietal
cortex,  cerebellum and thalamus)  whereas  our  study was performed in  cytokine-
stimulated  human  microglia  cells.  The  inflammatory  response  produced  in  our
experiments leads to a proliferation of microglia cells that was not evaluated in the
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Mitochondria Fig 24: Representation of signalling cascades
involving 14-3-3  protein
total brain. TBB1, a cytoskeletal protein with chaperone functions is probably more
expressed in stressed-microglia cells in order to support their proliferation, and this
could be associated with a higher level of complex TCP-1/TBB1. In the total brain,
up-regulation of TCP-1 in microglia is probably non-significant as compared to the
massive neuronal cell loss leading a decrease of TBB1 and TCP-1.
Our studies show a down-regulation of  other TCP-1 subunits: Epsilon (ε) and Eta
(H). These results are in line with former studies by Yoo and co-workers on human
parietal cortex (Yoo et al., 2001). These authors found decreased levels of the TCP-
1 subunit ε in AD brain. TCP-1 ε is involved in the regulation of the cell cycle and
decreased levels of TCP-1 ε may stop the cell cycle of brain cells in the G2/M phase.
Thus apoptosis may be initiated by p53/Bax pathway.
IV.1.1-5-   Role of proteins involved in cell communication and organization  
Pre B-cell enhancing factor (PBEF) was first isolated from activated lymphocytes and
has been proved to be involved in maturation of B-cells precursors (Ognjanovic et
al., 2001). PBEF-gene sequence contains several regulatory elements, suggesting
that  this  gene  may  be  chemically  and  mechanistically  responsive  to  inducers  of
transcription.  Studies  on  human  fetal  membranes  have  shown  that  PBEF  is
expressed in normal  cells  and is highly increased after  stimulation with cytokines
such as IL-1β and TNF-α.
 
The results of our studies have also shown an up-regulation of PBEF (1.8 fold) after
cytokines treatment of microglia cells.
IV.1.2- Down-regulated proteins
IV.1.2-1- Role of nucleoside diphosphate kinase A
One  of  the  most  down-regulated  proteins  found  after  cytokine  treatment  is
nucleoside diphosphate kinase A (NDKA).
NDKA, a protein of 17.3 KDa, is highly conserved through evolution. The function of
NDKA is related to cell proliferation and differentiation with an important role in the
cell  cycle  (Kim  et  al.,  2002).  NDKA  has  been  shown  to  be  co-localized  with
microtubules  present  at  synapses,  and  to  be  essential  for  normal  presynaptic
functions. The human A isoform is encoded by the nm23-H1 gene. In our study the
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expression of NDKA was decreased by 6.6 fold. This finding is in line with former
studies by Kim and co-workers (Kim et al., 2002). The authors reported that NDKA
activity  is  decreased  in  frontal,  occipital  and  parietal  cortices  of  AD  and  Down
syndrome patients. Modification of the kinase by oxidation has been reported as an
important functional regulator of inactivation of the NDKA kinase activity (Kim et al.,
2002).  This  supports  the  theory  of  an  important  involvement  of  oxidation  in
dementias like AD. Another participation of NDKA in AD and also in Down Syndrome
is by its effects on neuronal  differentiation such as neurite outgrowth.  Decreased
activity  of  NDKA  may  lead  to  altered  expression  of  cytoskeletal  proteins  which
participate in aberrant proliferation as described before (Kim et al., 2002).
IV.1.2-2-   Role of cyclin-dependent kinases  
CdK4  is  a  member  of  cyclin-dependent  kinases  (CdKs)  that  regulate  cell  cycle
progression  and  may  also  be  involved  in  neurodegenerative  disorders  via
deregulation of programmed cell death (Lim el al., 2003).
CdK4 is a major catalytic partner protein of D type cyclin in the phase G1/S. It has
multiple functions such as cell proliferation, survival, death and tumorigenesis. The
complex CdK4/cyclin has been shown to be induced in neuronal apoptosis (Tsujiota
et al., 1999).
Former studies revealed that CdK4 could only be detected in NFT bearing neurons in
AD brains, but Tsujiota and co-workers (Tsujiota  et al., 1999) found it also in diverse
cells such as astrocytes, neurons, oligodendrocytes and microglia. Moreover, these
studies reported higher levels of CdK4-mRNA expression in AD brains. 
Currently, these is no explanation for the contradictory results, except that the role of
CdK4  in  apoptosis  was  confirmed  and  its  expression  appears  to  be  more
pronounced in neurons than in other cell types.
IV.1.2-3-   Role of phosphatase 2A  
The serine/threonine phosphatase 2A (PP2A) has been suggested to be involved in
AD due to  its  regulatory  role  of  tau  and  MAP kinase dephosphorylation.  Former
studies in cultured fibroblasts have shown that impairment of PP2A in AD prevents
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the  ability  to  reverse the  hyperphosphorylation  of  tau  protein  and,  in  addition,  to
delay the ERK1/2 inactivation leading to tau phosphorylation (Zhao et al., 2003).
Our results correlate with previous findings, because in microglia cells,  PP2A was
found to be clearly down-regulated by pro-inflammatory cytokines.
IV.1.2-4-   Role of proteins involved in metabolism  
IF2A is a  protein  involved in  translation  of  proteins  as shown on Fig  25.  In  AD,
phosphorylation of IF2A has been found to inhibit protein translation and subsequent
induction of apoptosis. Studies made on human brain sections have shown a high
presence of phosphorylated IF2A in AD (Chang et al., 2002). However, our results
show a 2-fold down-regulation of IF2A, but its identification by mass spectrometry did
not reveal whether  this protein is phosphorylated or not.  As described previously,
phosphorylation of a protein changes its molecular weight: non-phosphorylated IF2A
was  down-regulated  whereas  phosphorylated  IF2A  was  not  detected.  This
discrepancy between published data and our findings may be due to the different
cellular models used.
An interesting  finding of our study is that two ubiquitin-conjugating enzymes, E1 and
E2,  are  found  to  be  down-regulated  in  cytokine-stimulated  microglia  cells.
Downregulation of ubiquitin proteasomes which are involved in the degradation of
secretases such as BACE (Quing et al., 2004) may be of key importance for Aβ-
mediated neurotoxocity and thus could play a major role in the pathogenesis of AD
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Fig  25: Cascade  representation  of  the
translation control of proteins. 
Involvement of the eukaryotic initiation
factor 2 alpha (eIF2A)
(Song  et  al.,  2003).  Our  results  confirm  former  findings  of  down-regulation  of
ubiquitin-conjugating enzyme E1 and E2 by Layfield and collaborators (Layfield et
al., 2003).
IV.1.2-5-   Role of proteins with oxidoreductase activity  
Peroxiredoxins  (PRX)  are  antioxidant  enzymes  found  in  six  different  isoforms  in
mammalians:  PRX  (I-VI).  For  example,  levels  of  peroxiredoxin  2  and  6  were
increased in human postmortem AD brains, whereas no change was observed in
Peroxiredoxin-1  (PRX1)  expression  (Krapfenbauer  et  al.  2003).  Our  results
demonstrate that   PRX-1, -2, and -3 expression  was decreased in the cytokine-
treated microglia cells. At present no explanation can be given to unsderstand these
controversial data.
To sum up, our results obtained with cytokine-stimulated microglia cells confirm a
significant  contribution  of  inflammatory  responses  and  a  key  role  of  activated
microglia  cells  in  the  neurodegenerative  process  of  AD.  Moreover,  most  of  the
proteins  found  with  altered  expression  levels  have  a  functional  role  in
neurotransmission,  in  axonal  transport,  in  signal  transduction,  or  are  involved  in
metabolism pathways. Thus, it is an attractive hypothesis to state that among these
proteins may be potential new drug targets.
After comparison with the transgenic mice model and human postmortem brain, the
conclusion  of  this  first  project  is  that  the  human microglia  cell  line  represents  a
valuable cellular model to mimic and to study inflammation processes occuring in AD
brains. This study allowed the identification and the description of several proteins
which are of  particular  interest  in  AD pathogenesis  and which could be used as
biological marker molecules and possibly help in the early diagnosis of the disease.
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VI.2-  CHARACTERIZATION  OF  NITRATED  PROTEINS  IN  A  TRANSGENIC  MOUSE
MODEL
The  participation  of  nitrative  oxidation  has  been  clearly  demonstrated  both  in
neurodegenerative and inflammatory disorders (Sarchielli et al., 2003). Nitration has
been reported to affect  protein  structure and function.  Former studies have been
performed by mass spectrometry in order to isolate nitrated proteins by isolation of
the amino acid sequence (Nikov et al., 2003; Butterfield et al., 2003; Marcotte et al.,
2003). A future aim would be to show the revelance of nitration for the development
and progression of neurodegenerative diseases (Sarchielli et al., 2003).
In  our  study,  previous  software  analyses  have  shown a  much  higher  number  of
nitrated peptides for  fructose 1-6 biphosphate aldolase than for a variety of  other
proteins. In mammals, three different fructose 1-6 biphosphate aldolase have been
described: aldolase A, B, and C. The aldolase B, present in liver, is involved in the
fructose utilization pathway. Aldolase A is more ubiquitous and is also present  in
brain. Aldolase C has been described as brain-specific.
Aldolase C has first  been found to  be  expressed in  brain  of  rodents  and in  the
Purkinje cells of the rat cerebellum. In human CNS, mRNA of this protein was found
to be expressed at low levels in brain cortex. Levels of mRNA gradually increase
extending from frontal and parietal cortex to the occipital cortex. Aldolase C is also
expressed in Purkinje cells of human cerebellum  (Buono et al., 2001).
Aldolase  is  a  glycolytic  enzyme  catalyzing  the  conversion  of  D-fructose  1,6
bisphosphate into glycerone phosphate and D glyceraldehydes 3 phosphate (Kanski
et al., 2003). An additional role of aldolase C as an actin binding protein, including a
role  in  actin  polymerization  has  been  described.  Binding  of  aldolase  C  to
microtubules  has  been  reported  to  occur  via  binding  to  α-tubulin.  This  binding
decreases the enzyme activity by about 90% (Schindler et al., 2001).
First of all, nitration of proteins has been correlated with ageing. In tissues of elderly
people,  nitrated  proteins  accumulate  faster  mostly  because  the  degradation  by
proteasomes is decreased with age (Kanski et al., 2003).
There  is  also  evidence  that  aldolase  suffers  nitration  after  nitric  oxide-induced
inflammation: studies on aldolase A have shown that tyrosine nitration of aldolase A
may contribute to an impairment of the glycolytic activity (Koeck et al., 2004); more
recent  studies  on  Purkinje  cells  by  Welsh  and  coworkers  (Welsh  et  al.,  2002)
revealed that after a global brain ischemia, these neurons dy more easily because of
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a deficiency in aldolase C. This finding strongly suggests a potent role of Aldolase C
on neuronal survival in response to injury such as hypoxia (Welsh et al., 2002).
At present, the involvement of Adolase C in AD is only speculative.  Little is known
about  the metabolic  events  correlated with cerebral  aging or  dementia  disorders.
During AD, there is a severe reduction of glucose comsumption. A key regulatory
enzyme for glycolysis is 6-phosphofructokinase (PKF). Postmortem studies of Bigl
and colleagues (Bigl et al., 1996) have shown that the PKF activity was significantly
increased in frontal and temporal cortex of AD patients. Authors found that aldolase
activity which converts the product of the PKF reaction, fructose 1, 6-biphosphate,
was unchanged. 
The theoretical part of our study showed an increased level of ALFC in AD by 1.26
fold that could not be shown by the Western blot analysis performed. This slight up-
regulation of the expression of the protein is a border line effect.
We postulate an increased levels of nitrated ALFC in AD as compared to control by
theoretical  studies  (1.4  fold),  but  the  difference  in  level  of  nitration  could  not  be
demonstrated  by  the  Co-immunoprecipitation  performed.  The  observation  of
regulation of the nitration level in the neurodegenerative process should be amplified
by increasing or decreasing the levels of protein expression. Our results indicate that
further  studies  should  be  performed  with  proteins  exhibiting a  higher  expression
change in AD in comparison with in control  samples.  In line with this, are recent
studies with the analysis of the ATPase synthase shown to be 10-fold induced in AD
brains as compared to controls.
Nitration of the last residues of ALFC protein may be the most important functional
change  that  can  occur:  studies  on  insects  done  by  Gavilanes  and  coworkers
(Gavilanes  et  al.,  1982)  have  shown  that  C  terminal  residues  are  essential  for
maintenance of  the catalytic conformation of  Aldolase.  However,  this modification
was detected only once in our studies, probably due to the fact  that  the different
peptides  do  not  have  the  same  facility  to  be  detected  during  the  analysis  by
MALDI/TOF. This may depend on their affinity to the matrix used in the proteomic
analyses.  In  conclusion,  proteomic  technology  has  proven  as  an  extraordinary
valuable  methology  which  allows  the  detection  and  analysis  of  each  protein
sequence.
Moreover,  during our  study other  nitrated proteins  were detected.  These proteins
could be potential biomarkers molecules to identify AD in patients. Proteins such as
tubulin beta 5, tubulin alpha1 chain or actin B may play a role in neurodegenerative
diseases such as AD due to their  functional role in microtubule stability.  Proteins
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such as the dihydropyrimidinase 2 (DPY2), involved in axonal growth and guidance
in the brain, have been shown to play a role in AD. Indeed in AD brains, DPY2 has
been found in a more oxidized form than in controls leading to neuritic degeneration
probably due to a lack of neuroprotective mechanisms in the brains (Castegna et al.,
2002). The protein, rab-gtp dissociation inhibitor alpha (GDIA) is another protein of
interest. GDIA is one the proteins controlling the activity of small GTPases of the rab
family involved in functional vesicle fusion and intracellular trafficking. Alterations of
GDIA expression can lead to impairment of synaptic vesicle exocytosis, a synaptic
dysfunction that occurs in the brain in AD (D’Adamo et al., 2002).
In summary, our studies confirm that post-translational changes such as nitration of
proteins  can  be  detected  and analysed with  proteomic  technologies.  Additionaly,
application of this technology can help to monitor other diseases-related changes in
functional proteins, for example phosphorylation and oxidation. 
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VI.3- Loss of synaptic connections in Alzheimer’s disease
VI.3.1- Map of cytosolic proteins of mouse brain
These experiments were performed with the cytosolic part of brains of control mice.
DEAE chromatography and  MS were  used  in  order  to  improve the  sensitivity of
detection of proteins involved in diverse pathways.
Recent studies have shown the importance of abnormal signaling pathways in the
pathogenesis of AD. For example, it has been demonstrated that the p38/mitogen
activated protein (MAP) kinase is one of the pathways overactivated in AD (Johnson
et  al.,  2003).  Currently  four  distinct  groups  of  MAP  kinases  are  known:  (i)  the
extracellular signal regulated kinases (ERKs); (ii) the c-jun N-terminal protein kinases
(JNKs);  (iii)  the  big MAP kinases  named BMK1 or  ERK5 and  (iv)  the  p38  MAP
kinases. The p38 enzyme is activated by MAP kinase kinases (MKKs) such as the
MKK6 that  phosphorylate all isoforms of p38. These MKKs are themselves activated
by MKK kinases such as MEKK4.
In AD, oligomeric Aβ is thought to activate signaling pathways and to increase p38
activity (Johnson et al., 2003). p38 may also play a role in Tau phosphorylation. In
fact,  recent  findings  indicate  that  tau  protein  is  a  downstream  target  of  kinases
activated  by  p38.  Previous  studies  revealed  that  inhibition  of  p38,  significantly
decreases brain injury and neurological deficits. Ongoing research supports the view
that p38 is a potential candidate for therapeutic treatment of AD.
Another pathway has been correlated with the Aβ neurotoxicity; the serin-threonine
kinase  (Akt)/  GSK-3β  (Suhura  et  al.,2003;  Zhang  et  al.,2001).  Akt  is  crucial  for
survival  of  neuronal  and  endothelial  cells,  growth  processes  and  glucose
metabolism. NGF activates trkA and signaling proteins of the rap1/Erk1,2; p38MAPK
and Pi3K pathways (Delcroix J.D. 2003). Neurotrophins such as NGF activate Akt
kinase which in turn promotes neuronal survival and inhibits apoptosis. In AD, injury
such as deposition of  Aβ or  lack of  neurotrophic  factors  such as NGF lead to a
disturbed Akt activation consistent with increased apoptosis of neurons.
In our study, the parallel use of chromatography and Mass spectrometry allowed the
detection of diverse proteins from different levels of the signaling pathways such as
Akt, MEKK and ERK. The detection of ERK 1 and ERK 2 are of considerable interest
because they belong to downstream kinases of the signaling pathway (Fig 26), such
sensitivity level has never been reached before. 
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Identification of kinases represented approximately 45% of all identified proteins in
the brain extracts. The first identification by mass-spectrometry of specific kinases
such as ERK 1  and  2  which  are downstream kinases  in  the  signal  transduction
pathway,  is  the  result  of  a  significant  improvement  of  the  sensitivity  of  the
technologies used. Indeed, the real protein amount for a MALDI-TOF detection is in
the attomolar range. However, there is loss due to peptide extraction from gel and
dilution to have enough volume for an automation of the process, the visible spots on
Coomassie-blue  stained  gel  were  represented  about  10-25ng  of  protein.  This
extremly low amount  for  a downstream protein of  the signaling pathways can be
achieved only by chromatography enrichment.
The functional implication of some of these proteins is represented in the cascade
shown below (Fig 26).  This cascade is  just  a part  of  the growth  factor  signaling
pathway,  from the  binding  of  the  growth  factor  to  a  specific  membrane receptor
leading to modulation of gene expression.
Our study proved that proteins of the signaling pathways possibly involved in AD are
detectable  by  proteomic  technologies  and  that  the  sensitivity  of  detection  is
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Fig 26: Representation of signaling
pathways of growth factors
significantly  improved  by  chromatography.  This  demonstrates  that  these
technologies  will  help  to  a  better  understanding  of  the  biochemical  processes
contributing to dysfunction and death of neurons in AD. Further investigation aims to
identify  the  different  modifications  that  can  occur  in  several  signaling  pathways
known to be involved in AD such as p38/MAP kinase pathway. 
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VI.4- ROLE OF SYNAPTOSOMES IN AD
Loss of neurons and synaptic connections has been shown in the pathology of AD
and correlates with the degree of dementia. For example, the synaptic density has
been shown to be decreased by 25 to 35% in AD cortex (Selkoe., 2002). Cholinergic
and  glutamatergic  neurons  appear  to  be  particularly  affected.  However,  little  is
known about the neurotoxic mechanisms involved in disease progression.
Evidence has been provided that impaired synaptic transmission in LTP occurs long
time before Aβ deposition. Moreover, synaptic dysfunction and subsequent neuron
loss starts to occur early during the presymptomatic phase of the human disease
(Bigio et al., 2002). Further studies by Rowan and co-workers provided evidence that
soluble Aβ peptides affect synaptic transmission, via interactions with the intracellular
signaling pathways, long time before the occurence of fibrillar Aβ peptides (Rowan et
al.  2003).  Aβ  inhibits  cholinergic  transmission  by  decreasing  the  synthesis  of
acetylcholine (ACh) or modulating of its release and degradation via activation of the
ERK pathway.  Based  on  the  studies  on  the  role  of  Aβ  in  diminishing  LTP  and
increasing LTD, Rowan hypothesized a model for the pathogenetic role of Aβ, as
shown in Fig 27.
Protein  patterns  of  synaptic  membranes  and  vesicle  membranes  required  for  a
functional neurotransmission are important. Characterization of changes in receptor
expression,  e.g  neurotrophin  receptors  or  in  cytoskeletal  proteins  that  lead  to  a
decreased neurotransmission should be performed in order  to understand and to
define  the site of the impairment of synaptic function in AD.
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Fig 27: Representation of the role of
Aβ peptide in early and late cognitive
dysfunctions
Our study clearly demonstrates that isolation of synaptosomes of brain is possible by
differential  fractionation.  Separation  of  cellular  components  was confirmed  by an
antibody against synaptophysin , a specific vesicle membrane-protein. 
In addition, we optimized the sensitivity of the proteomic technology to study samples
where proteins are expressed at low level and to have an efficient identification level
by the  development  of  minisystem technology.  Another  methodological  challenge
was to separate membrane proteins on 2D-gels. The development of the proteomic
technology including treatment  of  protein  solutions with specific  reagents such as
DTE  or  iodoacetamine,  lead  to  a  more  and  more  efficient  separation  of  these
membrane proteins. The future goal will be to create a map of synaptic membrane
proteins. This will be continued by a comparison of protein patterns in control and in
AD synaptic  membranes.  In addition,  further  studies will  aim to perform a kinetic
analysis of these changes, in order to better understand when specific modifications
in brain develop and when the synaptic failure in AD occurs. 
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V- OUTLOOK
Optimization of the techniques employed in these studies and the results on the in
vitro experiments form the basis for continuation of this project. A triple transgenic
mouse model  APP/PS2/IL-6 is being developed.  These mice should open up the
possibility of studying the role of  interleukin-6 (IL-6) in inflammatory processes as
well  as  in  amyloid  β deposition in brains.  Furthermore,  these  transgenic  animals
could help to distinguish between proteins involved in neurodegenerative processes
as compared to normal ageing.
In the future, it will be interesting to study other nitrated proteins found by theoretical
analysis. This project is still ongoing and  an interesting protein candidate is ATPase
synthase, which is highly overexpressed (10 fold) in diseased AD brains.
Other  proteins  such  as  TBB5,  TBA1  or  ACTB  which  are  cytoskeleton  binding
proteins  could  play  a  role  in  neurodegeneration  and  their  modifications  during
disease progression would be of interest.  This technology could also be used for
identification  of  other  conformational  protein  changes  due  to  inflammation,
phosphorylation or oxidation.
These improvements  in  technology should  help  to  detect  diverse proteins  at  low
expression levels in brain cells. The miniaturization of proteomic technology should
improve  the  separation  and  detection  of  membrane  proteins.  The  latter  were
previously difficult to identify in a 2D gel. 
The major goal will be to map the proteins in synaptosomal membranes of control
and AD transgenic mice and to extend these studies to neurons from diseased AD
brains. The methodologies developed in the course of this study form the basis for
focussed  molecular  and  cellular  analyses  of  abnormalities  in  neurodegenerative
processes.
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